Developers and designers of tomorrow’s cities triumph at the 20th PropertyGuru Asia Property Awards Grand Final ACN Newswire

Developers and designers of tomorrow’s cities triumph at the 20th PropertyGuru Asia Property Awards Grand Final

CULMINATION OF THE 2025 PROPERTYGURU ASIA PROPERTY AWARDS SERIES DISTINGUISHES THE BEST IN ASIA WITH OVER 90 MARKS OF EXCELLENCEBANGKOK, Dec 16, 2025 - (ACN Newswire via SeaPRwire.com) - The 20th edition of the PropertyGuru Asia Property Awards series has culminated in spectacular style at its Grand Final, distinguishing sublime real estate achievements across the region.After a landmark journey through 13 property markets, the 2025 PropertyGuru Asia Property Awards Grand Final set apart Asia’s outstanding developers, developments, and designs in ceremonies today at The Athenee Hotel, a Luxury Collection Hotel, Bangkok.Commemorating 20 years of recognising achievements in real estate, the PropertyGuru Asia Property Awards Grand Final featured over 90 categories celebrating the “Best in Asia,” in line with PropertyGuru’s vision of powering communities to live, work, and thrive in tomorrow’s cities. Finalists were chosen from the PropertyGuru Asia Property Awards’ series of galas and events across the region.Henderson Land Development Company Limited from Hong Kong brought home the prestigious golden statuette of Best Developer (Asia). The Legacy - 8 Castle Road, Mid Levels, Henderson Land Development Company Limited’s ultra-luxurious joint venture with leading developer New World Development Company Limited, achieved a double victory in the development and design categories.One Central Macau Revamp by Properties Sub F, Limited, a joint venture of Hongkong Land Group and Shun Tak Development Limited, also won and represented the Chinese special administrative regions. Design innovation from Mainland China was prominently recognised this year, with wins for top design practices Benoy, CAN Design, J&A Design, and Lead8.With a total of 17 Best in Asia titles, Malaysia was the top-performing country at the 2025 PropertyGuru Asia Property Awards Grand Final. JLand Group emerged victorious as Best Industrial Developer (Asia), winning for its township development Bandar Dato’ Onn. MTD Properties and Faire Development were named Best Affordable Residential Developer (Asia) and Best Breakthrough Developer (Asia), respectively.Malaysia’s honours were spread across diverse developments emphasising connectivity, sustainability, multi-generational flexibility, and premium living experiences. Other winning companies included Armani Group; Astaka Kimlun Sdn Bhd; City Motors Group; Exal (Malaysia) Sdn Bhd; Gunung Impian Development Sdn Bhd; IIB Land Sdn. Bhd.; Malton Berhad; Perbadanan Kemajuan Negeri Selangor (PKNS); Platinum Victory; R&F Development Sdn Bhd; Sime Darby Property; and TRX City Sdn Bhd.Indonesia followed closely with 15 wins for developers across the archipelago. Winners demonstrated their prowess in building live-work-play communities, with Paramount Land named Best Township Developer (Asia) and Sinar Mas Land winning for the townships BSD City and Grand Wisata. Sinar Mas Land also scored a joint win with Hongkong Land for Botanic Villa at NavaPark.PT. Putragaya Wahana, hailed Best Commercial Developer (Asia), earned multiple wins for the superblock Thamrin Nine, home to Indonesia’s tallest buildings. Winning projects by Mandiri Land, Masgroup, Summarecon Group, and Triniti Land set high benchmarks for affordable, mid-end, high-end, and eco-conscious living, as well as hospitality.With 14 wins, developers from Vietnam rose as another formidable force at the Grand Final, led by CapitaLand Development (Vietnam), winner of Best Sustainable Developer (Asia) and multiple honours for the projects Orchard Grand, Orchard Mansion, The Fullton, and The Orchard. Gamuda Land Vietnam won Best Community Developer (Asia), reinforced by projects such as Central Park and Springville. Nomura Real Estate Vietnam, awarded Best International Partner Developer (Asia), was additionally recognised for The Komorebi. Projects from Ecopark Founder and KD Investment Joint Stock Company rounded out the elite winners from Vietnam.Singapore developers received 11 wins, including Best Residential Developer (Asia) for UOL Group Limited. Parktown Residence, a venture of CapitaLand Development, UOL Group Limited, and Singapore Land Group Limited, scored three wins while Upperhouse at Orchard Boulevard delivered a joint win for UOL Group Limited and Singapore Land Group Limited. IOI Properties Singapore meanwhile achieved three wins across the projects IOI Central Boulevard Towers and W Residences Marina View. Honours for Allgreen Properties and The Assembly Place further underscored real estate excellence in the city-state.Developers across the Philippines won 10 Best in Asia titles. Robinsons Land received four titles, including the Best Luxury Developer (Asia) award and wins for The Mall | NUSTAR; The Victor at Bridgetowne; and work.able GBF Center 1. Robinsons Hotels and Resorts was named Best Hospitality Developer (Asia) while RLC Residences, a Robinsons Land subsidiary, won for Sync and The Residences at The Westin Manila. Winning developments from Aboitiz Economic Estates, Aboitiz Land, Inc., and FIESTA Communities Incorporated showcased the Philippines’ impressive progress in industrial development and housing connectivity.Thailand developers earned seven Best in Asia wins, led by Reignwood Group, winner of Best Luxury Mega Township Development (Asia) for Reignwood Park. Thailand’s wins underlined development innovations and architectural excellence throughout the kingdom, exemplified by luxurious homes and coastal residences by AP (Thailand) Public Company Limited, Pruksa Real Estate Public Company Limited, Triya, and Tropical Life Real Estate Co., Ltd. Solidifying Thailand's stature as a premier retail destination, Lead8 was honoured for its design on Parade at One Bangkok.Supaluck Umpujh, chairwoman of The Mall Group, received the PropertyGuru Icon Award from the editorial team of Property Report by PropertyGuru. The 2017 Thailand Real Estate Personality of the Year returned to the PropertyGuru Asia Property Awards in recognition of her recent iconic achievements in mixed-use and retail development, including the award-winning EM District in Bangkok.Eterno Property Group represented Australia’s enduring cross-border appeal to property seekers with wins for its projects Munro House and The Newlands. Eve Residences by Homecorp was recognised for its impressive views along the Australian coast.From Japan, JY Suites Tsutenkaku by Jean Yip Developments won the Best Affordable Condo Development (Asia) award while Four Seasons Hotel Osaka by Curiosity won Best Hospitality Interior Design (Asia).Representing Sri Lanka, Home Lands Group of Companies was named Best Lifestyle Developer (Asia) while Pentara Model Apartment by Urban space Interiors Pvt Ltd. won Best Condo Interior Design (Asia).From the Middle East, The Chedi Private Residences, Sheikh Zayed Road, Dubai, United Arab Emirates by Chedi Hospitality won Best Branded Residential Development (Asia).Jules Kay, general manager of PropertyGuru Asia Property Awards and Events, said: “We conclude the landmark 20th edition of the PropertyGuru Asia Property Awards series on a highly positive note, echoing industry resilience in over 600 awards across 13 distinct real estate markets that continue to overcome headwinds and capitalise on strategic opportunities in the current cycle. This year’s Best in Asia winners showcase record-setting skyscrapers, large-scale townships, transit-oriented developments, premium and affordable homes, flexible spaces, and urban landmarks, designed with ambition for long-term value and guided by environmental and social considerations. We look forward to the new standards of sustainable development that developers in Asia will deliver over the next 20 years.”Thien Duong, chairperson of the Grand Final jury and general director, GroupGSA (Vietnam), said: “The distinguished winners of the 20th PropertyGuru Asia Property Awards Grand Final have expertly answered the regional demand for experiential living, wellness integration, and future-proofed design. From integrated live-work-play communities to ultra-luxurious addresses and immersive sales galleries, the collective momentum is toward more sustainable, people-centric, and technologically adaptive projects. Our awardees demonstrate that exceptional master-planning, architecture, interior design, and landscaping can be achieved at any scale, ultimately driving tenant retention, buyer attraction, and the creation of civic assets that enrich the urban fabric. Congratulations to the Best in Asia.”The winners were selected by a jury comprising the head judges of participating markets in the Awards: Thien Duong; Ajai A Kapoor, CEO, 360 degrees – Real Estate Services (India); Cyndy Tan Jarabata, president of TAJARA Leisure & Hospitality Group Inc. (Philippines); Doddy A. Tjahjadi, managing director, PTI Architects (Indonesia); Eddie Guillemette, CEO, Midori no Ki (Japan); Datuk Ar. Ezumi Harzani Ismail, president, Malaysian Institute of Architects: 2020-2022 (Malaysia); Ivan Lam, executive director, international business, Charter Keck Cramer (Australia); Ken Ip, chairman, Asia MarTech Society (Mainland China); Dr. Nirmal De Silva, director and CEO, Paramount Realty (Sri Lanka); Paul Tse, president, Macao Association of Building Contractors and Developers (Hong Kong and Macau); Roy Ling, CEO, board director, and adjunct professor, FollowTrade (Singapore); and Suphin Mechuchep, strategic real estate advisor (Thailand).HLB, the global network of independent professional accounting firms and business advisers, upheld the integrity of the awards. Paul Ashburn of HLB International Real Estate Group and Sakanphon Fueangwong of HLB Thailand oversaw the selection process.The PropertyGuru Asia Property Awards Grand Final is supported by platinum sponsor Sub-Zero & Wolf SEA; official portal partner PropertyGuru; official magazine Property Report by PropertyGuru; media partners Bridges, BusinessWorld, d+a Magazine, Detik.com, Hot Magazine, Inquirer Property, Kompas.com, Kopi and Property, Luxury Society of Asia, Manila Bulletin, Niaga Times, Penang Property Talk, Prop2morrow, REm Thailand, SquareRooms, Tatler Asia Homes, TerraBKK, The Grid, The Malaysia Voice, The Philippine Star, and Top10 of Asia; official courier EZY Express; and official supervisor HLB.For more information, email awards@propertyguru.com or visit the official website: AsiaPropertyAwards.com.COMPLETE LIST OF WINNERS20th PropertyGuru Asia Property Awards Grand FinalDEVELOPER AWARDSBest Developer (Asia)Henderson Land Development Company Limited – China – Hong Kong and Macau (WINNER)Eterno Property Group – AustraliaHome Lands Group of Companies – Sri LankaJean Yip Developments – JapanJLand Group – MalaysiaRobinsons Land – PhilippinesSummarecon Group – IndonesiaBest Township Developer (Asia)Paramount Land – Indonesia (WINNER)Phu Long Real Estate Corporation – VietnamBest Luxury Developer (Asia)Robinsons Land – Philippines (WINNER)Allgreen Properties Limited – SingaporeSkyland Group – AustraliaBest Commercial Developer (Asia)PT. Putragaya Wahana – Indonesia (WINNER)Robinsons Offices – PhilippinesBest Industrial Developer (Asia)JLand Group – Malaysia (WINNER)Aboitiz Economic Estates – PhilippinesBest Hospitality Developer (Asia)Robinsons Hotels and Resorts – Philippines (WINNER)Best Lifestyle Developer (Asia)Home Lands Group of Companies – Sri Lanka (WINNER)Jean Yip Developments – JapanBest Sustainable Developer (Asia)CapitaLand Development (Vietnam) – Vietnam (WINNER)Berinda Group – MalaysiaRobinsons Land – PhilippinesUOL Group Limited – SingaporeBest Residential Developer (Asia)UOL Group Limited – Singapore (WINNER)Best Affordable Residential Developer (Asia)MTD Properties – Malaysia (WINNER)FIESTA Communities Incorporated – PhilippinesKim Oanh Land – VietnamBest Community Developer (Asia)Gamuda Land Vietnam – Vietnam (WINNER)Best Breakthrough Developer (Asia)Faire Development – Malaysia (WINNER)Apex Asia Development Pte. Ltd. – SingaporeBest International Partner Developer (Asia)Nomura Real Estate Vietnam – Vietnam (WINNER)DEVELOPMENT AWARDSBest Mega Township Development (Asia)BSD City by Sinar Mas Land – Indonesia (WINNER)Kota Baru Parahyangan by PT Belaputera Intiland – IndonesiaBest Luxury Mega Township Development (Asia)Reignwood Park by Reignwood Group – Thailand (WINNER)Best Township Development (Asia)Bandar Dato’ Onn by JLand Group – Malaysia (WINNER)One Era by Hoa Lan Township JVC – VietnamSummarecon Bandung by Summarecon Group – IndonesiaSummarecon Serpong by Summarecon Group – IndonesiaBest Mixed Use Development (Asia)Tun Razak Exchange by TRX City Sdn Bhd – Malaysia (WINNER)Avia Estate by Alsons Development and Investment Corporation – PhilippinesHighwood - 70 To Kwa Wan Road by Henderson Land Development Company Limited – China – Hong Kong and MacauParktown Residence by CapitaLand Development, UOL Group Limited, & Singapore Land Group Limited – SingaporeBest Completed Mixed Use Development (Asia)Thamrin Nine by PT. Putragaya Wahana – Indonesia (WINNER)Best Industrial Development (Asia)LIMA Estate by Aboitiz Economic Estates – Philippines (WINNER)Industropolis Batang SEZ by PT Kawasan Industri Terpadu Batang – IndonesiaBest Lifestyle Commercial Development (Asia)Agora at Thamrin Nine by PT. Putragaya Wahana – Indonesia (WINNER)Odeon by UOL Group Limited – SingaporeBest Green Commercial Development (Asia)One Central Macau Revamp by Properties Sub F, Limited (Joint Venture of Hongkong Land Group & Shun Tak Development Limited) – China – Hong Kong and Macau (WINNER)GBF Centers 1 & 2 by Robinsons Offices – PhilippinesBest Eco Friendly Commercial Development (Asia)Teras Lakon at Summarecon Serpong by Summarecon Group – Indonesia (WINNER)Best Office Development (Asia)IOI Central Boulevard Towers by IOI Properties Singapore – Singapore (WINNER)Luminary Tower at Thamrin Nine by PT. Putragaya Wahana – IndonesiaYokohama Symphostage by Obayashi Corporation – JapanBest Retail Development (Asia)JLC by CAN Design – Mainland China (WINNER)Jakarta Premium Outlets by Genting Simon Group – IndonesiaBest Lifestyle Retail Development (Asia)The Mall | NUSTAR by Robinsons Land – Philippines (WINNER)Best Hospitality Development (Asia)Holiday Inn Resort Bintan Lagoi Beach by Mandiri Land – Indonesia (WINNER)Best City Hotel Development (Asia)Holiday Inn KL Bangsar by City Motors Group – Malaysia (WINNER)Fili Hotel Bridgetowne by Robinsons Hotels and Resorts – PhilippinesSocial on Outram by The Assembly Place – SingaporeBest Ultra Luxury Condo Development (Asia)Armani Hallson KLCC by Armani Group – Malaysia (WINNER)W Residences Marina View – Singapore by IOI Properties Singapore – SingaporeBest Luxury Condo Development (Asia)Upperhouse at Orchard Boulevard by UOL Group Limited & Singapore Land Group Limited – Singapore (WINNER)Pentara Residencies - Thummulla Handiya "The Address in Colombo" by Home Lands Group of Companies – Sri LankaBest Condo Development (Asia)Parktown Residence by CapitaLand Development, UOL Group Limited, & Singapore Land Group Limited – Singapore (WINNER)33–47A Elgin Street by Henderson Land Development Company Limited – China – Hong Kong and MacauBest Completed Ultra Luxury Condo Development (Asia)The Legacy - 8 Castle Road, Mid Levels by Henderson Land Development Company Limited & New World Development Company Limited – China – Hong Kong and Macau (WINNER)Best Completed Luxury Condo Development (Asia)The Residences at The Westin Manila by RLC Residences – Philippines (WINNER)Best Completed Condo Development (Asia)Munro House by Eterno Property Group – Australia (WINNER)Santorini Resort Apartments & Residencies, Negombo by Home Lands Group of Companies – Sri LankaBest Waterfront Condo Development (Asia)Central Park by Gamuda Land Vietnam – Vietnam (WINNER)Bayfonte Marina Resort Apartments & Villas, Negombo by Home Lands Group of Companies – Sri LankaChapter Charoenkrung Riverside by Pruksa Real Estate Public Company Limited – ThailandWanda View by 16MC Developments – AustraliaBest Lifestyle Condo Development (Asia)W Residences Marina View – Singapore by IOI Properties Singapore – Singapore (WINNER)The Zenith by Xiangyuan Property Development Limited – China – Hong Kong and MacauBest Mid End Condo Development (Asia)Sync by RLC Residences – Philippines (WINNER)Best High End Condo Development (Asia)Orchard Grand by CapitaLand Development (Vietnam) – Vietnam (WINNER)Best Connectivity Condo Development (Asia)Linkar 52 by Perbadanan Kemajuan Negeri Selangor (PKNS) – Malaysia (WINNER)Best Luxury Lifestyle Condo Development (Asia)Arden Serviced Residence by Astaka Kimlun Sdn Bhd – Malaysia (WINNER)Best Oceanview Condo Development (Asia)Eve Residences by Homecorp – Australia (WINNER)Best Affordable Condo Development (Asia)JY Suites Tsutenkaku by Jean Yip Developments – Japan (WINNER)Best Investment Condo Development (Asia)R&F Princess Cove Phase 2 - Seine Region by R&F Development Sdn Bhd – Malaysia (WINNER)Best Multigeneration Living Condo Development (Asia)PV22 Residences by Platinum Victory – Malaysia (WINNER)Best Ultra Luxury Housing / Landed Development (Asia)Botanic Villa at NavaPark by PT. Bumi Parama Wisesa (Hongkong Land & Sinar Mas Land) – Indonesia (WINNER)Best Luxury Housing / Landed Development (Asia)The Fullton by CapitaLand Development (Vietnam) – Vietnam (WINNER)Ardea at Summarecon Serpong by Summarecon Group – IndonesiaMatera Signature by Paramount Land – IndonesiaSango Project by Sango Construction Co., Ltd. – JapanBest Housing / Landed Development (Asia)Orchard Mansion by CapitaLand Development (Vietnam) – Vietnam (WINNER)Narra Park Residences Avia by Alsons Development and Investment Corporation – PhilippinesSpringleaf Collection by The Assembly Place – SingaporeUniversity Road Developments by Jean Yip Developments – SingaporeBest Affordable Housing / Landed Development (Asia)Areum Parc Bogor by Masgroup – Indonesia (WINNER)Sunnyhomes by SMDC Symphony Homes – PhilippinesBest Waterfront Housing / Landed Development (Asia)Seafront Residences by Aboitiz Land, Inc. – Philippines (WINNER)Best High End Housing / Landed Development (Asia)Bukit Impian Residence by Gunung Impian Development Sdn Bhd – Malaysia (WINNER)Best Mid End Housing / Landed Development (Asia)Vanica Residence at Summarecon Crown Gading by Summarecon Group – Indonesia (WINNER)baé by Faire Development – MalaysiaBest Luxury Lifestyle Housing / Landed Development (Asia)The Palazzo Pinklao - Borom by AP (Thailand) Public Company Limited – Thailand (WINNER)Best Lifestyle Housing / Landed Development (Asia)European Island, Eco Central Park by Ecopark Founder – Vietnam (WINNER)Giva at The Kaia by Sinar Mas Land – IndonesiaPonderosa Vista by Berinda Group – MalaysiaBest Completed Housing / Landed Development (Asia)The Orchard by CapitaLand Development (Vietnam) – Vietnam (WINNER)Best Eco Friendly Housing Development (Asia)Elmina Ridge 1 by Sime Darby Property – Malaysia (WINNER)Best Oceanview Housing / Landed Development (Asia)Nathee/Thawee by Tropical Life Residence by Tropical Life Real Estate Co., Ltd. – Thailand (WINNER)Best Multigeneration Living Housing / Landed Development (Asia)SÓL Estate Prime by Exal (Malaysia) Sdn Bhd – Malaysia (WINNER)Best Connectivity Housing / Landed Development (Asia)FIESTA Communities Aguso by FIESTA Communities Incorporated – Philippines (WINNER)Best Townhouse Development (Asia)Springville by Gamuda Land Vietnam – Vietnam (WINNER)Aludra Residensi by Perbadanan Kemajuan Negeri Selangor (PKNS) – MalaysiaBest Branded Residential Development (Asia)The Chedi Private Residences, Sheikh Zayed Road, Dubai, United Arab Emirates by Chedi Hospitality – Middle East (WINNER)Best Wellness Residential Development (Asia)The Komorebi by Nomura Real Estate Vietnam – Vietnam (WINNER)Best Nature Integrated Development (Asia)The Newlands by Eterno Property Group – Australia (WINNER)The Hood at Summarecon Serpong by Summarecon Group – IndonesiaBest Serviced Apartment Development (Asia)Park Green Pavilion Bukit Jalil by Malton Berhad – Malaysia (WINNER)DESIGN AWARDSBest Township Masterplan Design (Asia)Grand Wisata by Sinar Mas Land – Indonesia (WINNER)Taman Impian Emas by Gunung Impian Development Sdn Bhd – MalaysiaBest Mixed Use Architectural Design (Asia)Nanjing Alibaba Center by Benoy – Mainland China (WINNER)Menara Jakarta by ASRI - ( subsidiary of ASG ) Agung Sedayu Group – IndonesiaBest Office Architectural Design (Asia)IOI Central Boulevard Towers by IOI Properties Singapore – Singapore (WINNER)GBF Center 2 by Robinsons Offices – PhilippinesBest Retail Architectural Design (Asia)Shanghai Qianwan Incity MEGA by Lead8 – Mainland China (WINNER)K Mall at Menara Jakarta by ASRI - ( subsidiary of ASG ) Agung Sedayu Group – IndonesiaKato Knife Gallery and Workshop by BAUM Ltd. – JapanParade at One Bangkok by Lead8 – ThailandSKP Wuhan by Sybarite Architects – Mainland ChinaThe Mall | NUSTAR by Robinsons Land – PhilippinesBest Hospitality Architectural Design (Asia)Hotel Indigo Bintan Lagoi Beach by Mandiri Land – Indonesia (WINNER)ILUVIO Resort Motobu by K2-Design Architect & Associates Co., Ltd. – JapanBest Luxury Condo Architectural Design (Asia)Promenade Peak by Allgreen Properties Limited – Singapore (WINNER)Best Condo Architectural Design (Asia)Parktown Residence by CapitaLand Development, UOL Group Limited, & Singapore Land Group Limited – Singapore (WINNER)Best Ultra Luxury Housing / Landed Architectural Design (Asia)Triya Panwa by The Element by Triya – Thailand (WINNER)Best Luxury Housing / Landed Architectural Design (Asia)The Reserve Villas Sukhumvit 89/1 by Pruksa Real Estate Public Company Limited – Thailand (WINNER)Xandari at Summarecon Bandung by Summarecon Group – IndonesiaBest Housing / Landed Architectural Design (Asia)La Tiên Villa Subdivision – Libera Nha Trang by KD Investment Joint Stock Company – Vietnam (WINNER)The City Ratchapruek - Phrannok by AP (Thailand) Public Company Limited – ThailandBest High End Housing / Landed Architectural Design (Asia)Sequoia Hills – Cluster Harvest Ville by Triniti Land – Indonesia (WINNER)Best Affordable Housing / Landed Architectural Design (Asia)Areum Parc Bogor by Masgroup – Indonesia (WINNER)Best Townhouse Architectural Design (Asia)Wawari West Park Homes by IIB Land Sdn. Bhd. – Malaysia (WINNER)Best Sales Gallery Architectural Design (Asia)Galeria SA Sentral by Perbadanan Kemajuan Negeri Selangor (PKNS) – Malaysia (WINNER)Summarecon Bogor by Summarecon Group – IndonesiaW Residences Marina View – Singapore by IOI Properties Singapore – SingaporeBest Retail Interior Design (Asia)Parade at One Bangkok by Lead8 – Thailand (WINNER)Kato Knife Gallery and Workshop by BAUM Ltd. – JapanLiving World Kota Wisata Cibubur by PT Sahabat Kota Wisata (JV between Kawan Lama Group & Sinar Mas Land) – IndonesiaNanjing Jinling Place by Lead8 – Mainland ChinaThe Mall | NUSTAR by Robinsons Land – PhilippinesBest Office Interior Design (Asia)Shanghai Midea Global Innovation Park by J&A Design – Mainland China (WINNER)GBF Center 2 by Robinsons Offices – PhilippinesBest Hospitality Interior Design (Asia)Four Seasons Hotel Osaka by Curiosity – Japan (WINNER)25hours Hotel The Oddbird Jakarta by ASRI - ( subsidiary of ASG ) Agung Sedayu Group – IndonesiaILUVIO Resort Motobu by K2-Design Architect & Associates Co., Ltd. – JapanW Singapore - Marina View by IOI Properties Singapore – SingaporeBest Ultra Luxury Condo Interior Design (Asia)The Legacy - 8 Castle Road, Mid Levels by Henderson Land Development Company Limited & New World Development Company Limited – China – Hong Kong and Macau (WINNER)W Residences Marina View – Singapore by IOI Properties Singapore – SingaporeBest Luxury Condo Interior Design (Asia)Upperhouse at Orchard Boulevard by UOL Group Limited & Singapore Land Group Limited – Singapore (WINNER)Best Condo Interior Design (Asia)Pentara Model Apartment by Urbanspace Interiors Pvt Ltd. – Sri Lanka (WINNER)Best Housing / Landed Interior Design (Asia)Beon Kaset - Nawamin by AP (Thailand) Public Company Limited – Thailand (WINNER)Royale Residence by DM Projects Group – IndonesiaBest Commercial Landscape Design (Asia)Hotel Indigo Bintan Lagoi Beach by Mandiri Land – Indonesia (WINNER)Best Condo Landscape Design (Asia)Parktown Residence by CapitaLand Development, UOL Group Limited, & Singapore Land Group Limited – Singapore (WINNER)Best Housing / Landed Landscape Design (Asia)The Fullton by CapitaLand Development (Vietnam) – Vietnam (WINNER)Centro Sathorn - Suksawat by AP (Thailand) Public Company Limited – ThailandBest Townhouse Landscape Design (Asia)Springville by Gamuda Land Vietnam – Vietnam (WINNER)Wawari West Park Homes by IIB Land Sdn. Bhd. – MalaysiaBest Landmark Design (Asia)The Victor at Bridgetowne by Robinsons Land – Philippines (WINNER)Best Co Working Space (Asia)work.able GBF Center 1 by Robinsons Land – Philippines (WINNER)Best Co Living Space (Asia) Serene Living, managed by The Assembly Place – Singapore (WINNER)INDIVIDUAL AWARDPropertyGuru Icon AwardSupaluck Umpujh, Chairwoman, The Mall Group (WINNER)ABOUT PROPERTYGURU ASIA PROPERTY AWARDS:PropertyGuru’s Asia Property Awards, established in 2005, are the region’s most exclusive and prestigious real estate awards programme. The Asia Property Awards are recognised as the ultimate hallmark of excellence in the Asian property sector. Boasting an independent panel of industry experts and trusted supervisors, the Awards have an unparalleled reputation for being credible, ethical, fair, and transparent. In 2025, the Awards series is open to key property markets around the region. The exciting gala events welcome senior industry leaders and top media, as well as reach property agents and consumers via live streaming. Recognising excellence within each Asian market with a variety of categories, including green and sustainable development, each local awards programme will culminate in the PropertyGuru Asia Property Awards Grand Final, which takes place after the PropertyGuru Asia Real Estate Summit during PropertyGuru Week in December 2025. For more information, please visit AsiaPropertyAwards.com.ABOUT PROPERTYGURU GROUP:PropertyGuru is Southeast Asia’s leading1 PropTech company, and the preferred destination for over 32 million property seekers monthly2 to connect with over 50,000 agents3 monthly to find their dream home. PropertyGuru empowers property seekers with more than 2.1 million real estate listings4, in-depth insights, and solutions that enable them to make confident property decisions across Singapore, Malaysia, Thailand, and Vietnam.PropertyGuru.com.sg was launched in Singapore in 2007 and since then, PropertyGuru Group has made the property journey a transparent one for property seekers in Southeast Asia. In the last 18 years, PropertyGuru has grown into a high-growth PropTech company with a robust portfolio including leading property marketplaces and award-winning mobile apps across its markets in Singapore, Malaysia, Vietnam, and Thailand as well as the region’s biggest and most respected industry recognition platform – PropertyGuru Asia Property Awards, events, and publications across Asia.For more information, please visit: PropertyGuruGroup.com; PropertyGuru Group on LinkedIn.(1) Based on SimilarWeb data between July 2024 and December 2024.(2) Based on Google Analytics data between July 2024 and December 2024.(3) Based on data between October 2024 and December 2024.(4) Based on data between July 2024 and December 2024.PROPERTYGURU CONTACTS:General Enquiries:Richard Allan Aquino, Head of Brand & Marketing ServicesM: +66 92 954 4154E: allan@propertyguru.com Sales, Nominations, & Sponsorships:Udomluk Suwan, Sales DirectorM: +66 87 699 4433E: may@propertyguru.comMedia & Partnerships:Nate Dacua, Senior Manager, Media and Marketing ServicesM: +66 92 701 2510E: nate@propertyguru.comPiyachanok Raungpaka, Senior Media & Marketing Services ExecutiveM: +66 94 887 5163E: piyachanok@propertyguru.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
「周大福人壽」App為全港首個人壽保險應用程式開通AlipayHK繳保費 ACN Newswire

「周大福人壽」App為全港首個人壽保險應用程式開通AlipayHK繳保費

香港, 2025年12月16日 - (亞太商訊 via SeaPRwire.com) - 周大福人壽與AlipayHK宣佈合作,其應用程式成為香港首間人壽保險公司開通AlipayHK付款*,簡化保費繳付流程,提升服務效率與客戶體驗。周大福人壽客戶再無需手動輸入信用卡或賬戶信息,即可一鍵完成保費繳付,大幅減少繁複操作步驟以節省時間,創業界先河。隨著客戶對各類型的金融服務要求日漸增加,周大福人壽將陸續開通AlipayHK支付方式,全面支持數碼化新保單投保與續期保費繳交,進一步推動保險機構無紙化和數碼創新。周大福人壽執行董事兼行政總裁葉文傑表示:「周大福人壽一直以客戶為中心,與時並進,致力為客戶帶來更多體驗和服務。AlipayHK 在港擁有龐大的活躍用戶,雙方合作可充分發揮協同效應,為客戶帶來更便利、高效、安全和生活化的繳費體驗。未來,我們將繼續『開創保險新價值』,積極透過創新科技及跨界別合作,為客戶在人生不同階段提供更全面的支援。」AlipayHK行政總裁李詠詩表示:「AlipayHK致力與金融機構夥伴共建數字生態,推動香港金融生態數字化升級,讓普惠金融服務觸達更多市民。目前AlipayHK 超過450萬活躍用戶中,已有100萬是我們的理財用戶,印證市民對數字化財富管理服務的認可。此次與周大福人壽達成合作,正是基於用戶日益增長的理財需求,通過數字支付解決方案重塑投保流程,讓用戶能夠更高效地規劃個人資產配置。」早前周大福人壽於流動應用程式中推出「支付易 ePay」功能,讓客戶隨時隨地管理已累積的保單價值,從而提升客戶體驗並得到正面的迴響。今次與AlipayHK的合作更提升了保費繳付方式,是次合作展現周大福人壽與 AlipayHK 的跨界協作效應。周大福人壽將繼續結合周大福集團生態圈的資源,為客戶帶來更多便捷、貼近生活的保險產品及服務,陪伴客戶於「生活、成長、健康、傳承」的每一階段。* 截至2025年12月15日周大福人壽執行董事兼行政總裁葉文傑(右) 及AlipayHK行政總裁李詠詩(左) 宣佈周大福人壽應用程式成為香港首間人壽保險公司開通AlipayHK付款。關於周大福人壽周大福人壽保險有限公司(「周大福人壽」)扎根香港40年,為周大福創建有限公司(「周大福創建」)(香港股份代號:659)的全資附屬公司,也是香港最具規模的壽險公司之一。作為周大福企業成員,周大福人壽緊扣鄭氏家族(「周大福集團」或「集團」)生態圈的雄厚資源,致力為客戶及其摯愛於「生活、成長、健康、傳承」的人生旅程中,提供個人化的匠心規劃、終身保障及優質體驗。憑藉集團財務實力及環球投資佈局,周大福人壽矢志成為亞太區領先的保險公司,持續開創保險新價值。關於AlipayHKAlipayHK 電子錢包,是由Alipay Financial Services (HK) Limited(儲值支付工具牌照編號:SVF0004)營運,並由香港金管局監管。目前,全港已有逾150,000間零售商戶支援AlipayHK付款,涵蓋大型連鎖店、商店、便利店、超市、街市及食肆,而AlipayHK電子錢包付款服務更支援其他國家及地區,包括中國內地、日本、韓國、泰國、新加坡及馬來西亞等。更多詳細資料請瀏覽http://www.alipayhk.com。AlipayHK 不僅提供付款服務,亦是一個全方位的數碼生活平台,為香港用戶提供各式各樣的生活消閒及便利服務。服務涵蓋公共交通、理財、跨境付款、P2P 轉賬、派利是、匯款、繳費服務、購買第三方提供的保險產品、領取電子禮券等。讓香港市民享受這個劃時代的多功能電子錢包所帶來的便利體驗。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
CTF Life App Becomes Hong Kong’s First Life Insurance Mobile Application to Enable Premium Payments via AlipayHK ACN Newswire

CTF Life App Becomes Hong Kong’s First Life Insurance Mobile Application to Enable Premium Payments via AlipayHK

HONG KONG, December 16, 2025 - (ACN Newswire via SeaPRwire.com) – CTF Life and AlipayHK jointly announce a collaboration that makes CTF Life’s mobile application the first among Hong Kong life insurers* to enable premium payments via AlipayHK. This partnership streamlines the premium payment process, enhances service efficiency and elevates customer experience. With just one click, customers can settle premium payments without having to manually enter credit card or account details. This feature significantly reduces unnecessary steps, saves time and sets a new industry benchmark.In response to growing customer demand for a wider range of financial services, CTF Life will gradually enable AlipayHK as a payment option. This initiative fully supports the digitalisation of new policy applications and renewal premium payments, further driving the transformation toward paperless operations and digital innovation within the insurance industry.Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life, said, “CTF Life has always been customer-centric and forward-thinking, committed to delivering quality experiences and services to our customers. AlipayHK has a large base of active users in Hong Kong, and this collaboration fully leverages our synergies to provide customers with a more convenient, efficient, secure, and lifestyle-oriented payment experience. Moving forward, we will continue to create value beyond insurance by embracing innovative technologies and cross-sector collaborations to offer comprehensive support for customers at every stage of life.”Venetia Lee, CEO of AlipayHK, said, “AlipayHK is committed to collaborating with financial institutions to build a digital ecosystem, drive the digital upgrade of Hong Kong’s financial sector, and deliver more inclusive financial services to more citizens. Among AlipayHK’s over 4.5 million active users, one million are our wealth management users, which demonstrates public recognition of digital wealth management services. The partnership with CTF Life addresses users’ increasing wealth management needs by leveraging digital payment solutions to reshape the insurance application process, enabling users to manage and allocate their assets more efficiently.”CTF Life previously introduced the “ePay” feature on its mobile app, allowing customers to manage their accumulated policy value anytime and anywhere to enhance customer experience – a move that received positive feedback. This collaboration further enhances premium payment options, demonstrating the cross-industry synergy between CTF Life and AlipayHK. CTF Life will continue to harness resources from the Chow Tai Fook Group ecosystem to bring customers more convenient and lifestyle-oriented insurance products and services, accompanying customers throughput their life journey – from wellbeing, growth, and healthcare to legacy.* As of 15 December 2025Man Kit Ip, Executive Director and Chief Executive Officer of CTF Life (right) and Venetia Lee, CEO of AlipayHK (left) jointly announce a collaboration that makes CTF Life’s mobile application the first among Hong Kong life insurers to enable premium payments via AlipayHK.About CTF LifeChow Tai Fook Life Insurance Company Limited (“CTF Life”) is proud of its rich, 40-year legacy in Hong Kong. CTF Life is a wholly-owned subsidiary of CTF Services Limited (“CTFS”) (Hong Kong Stock Code: 659) and one of the most well-established life insurance companies in Hong Kong. As a member of Chow Tai Fook Enterprises Limited, CTF Life consistently strengthens its collaboration with the Chow Tai Fook Group ecosystem to support customers and their loved ones in navigating life’s journey with personalised planning solutions, lifelong protection and diverse lifestyle experiences. By leveraging the Group’s robust financial strength and strategic investments across the globe, CTF Life aspires to become a leading insurance company in Asia while continuously creating value beyond insurance.About AlipayHKThe AlipayHK electronic wallet is operated by Alipay Financial Services (HK) Limited (Stored Value Facility Licence number: SVF0004) and regulated by the Hong Kong Monetary Authority. Currently, over 150,000 local retail outlets support AlipayHK electronic wallet for payments, covering large chain stores, shops, convenience stores, supermarkets, markets, and restaurants. Additionally, AlipayHK electronic wallet payment service also supports multiple overseas countries, including Chinese Mainland, Japan, South Korea, Thailand, Singapore, and Malaysia. For more details, please visit: http://www.alipayhk.com.Apart from payment services, AlipayHK also serves as a comprehensive digital lifestyle platform, offering Hong Kong users a wide range of lifestyle, leisure, and convenience services. Features include transportation, financial management, cross-border payments, P2P transfers, blockchain remittances, bill payments, purchasing insurance products offered by third parties, and receiving electronic vouchers. This allows Hong Kong citizens to enjoy the convenience brought by this revolutionary multifunctional electronic wallet. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
New APAC Partnership with Matter Brings Market Logic Software’s Always-On Insights Solutions to Local Brand and Experience Leaders ACN Newswire

New APAC Partnership with Matter Brings Market Logic Software’s Always-On Insights Solutions to Local Brand and Experience Leaders

BERLIN, Germany, Dec 16, 2025 - (ACN Newswire via SeaPRwire.com) - Market Logic Software, the market-leading SaaS provider of insight management solutions, has announced a partnership with Matter, a New Zealand-based intelligence company for brand builders and experience creators. This collaboration marks an exciting step in Market Logic's expansion across APAC, particularly in New Zealand and Australia, where Matter is working closely with local brands that want to deepen their customer and market understanding.Together, Market Logic and Matter will empower APAC businesses to uncover unique insights faster and take swifter action. By combining the power of Market Logic's AI-powered insights platform, DeepSights, with the data, research and measurement expertise of Matter, the two companies will help ambitious local brands drive international growth through intelligence."New Zealand and Australia are home to exceptional brands who are no strangers to innovation and creativity," said Oliver Allen. "By combining our strategic and creative intelligence with DeepSights' market leading AI capabilities, we're helping these teams accelerate confident decision-making. We believe the real magic happens when smart, industry leading technology is combined with deep research, cultural and insights expertise, and that's what we hope to deliver through this partnership.""Matter understands the unique dynamics of APAC brands and the consumers they serve," said Maarten Sambre, SVP Global Sales at Market Logic Software. "With DeepSights, we can support these organisations with verified insights at speed, while Matter ensures those insights translate into smart, creative brand and experience strategies."This partnership also represents a shared commitment to supporting APAC's rapidly evolving insights landscape, where the demand for AI-powered intelligence continues to accelerate. Market Logic and Matter will collaborate on brand engagements, regional activation campaigns, and thought leadership focused on smarter, insight-led decision making.For more information about the partnership, please contact:Daniela ZuinCMOMarket Logic Softwaredaniela.zuin@marketlogicsoftware.comTel: +44 7799 113040Oliver AllenPartnerMatteroliver.allen@matter.nzTel: +64 27 448 6008About Market Logic SoftwareMarket Logic is the leading SaaS provider of market intelligence and insights solutions. Powered by our special purpose AI for Insights technology DeepSights, our platform allows insights teams and business decisions makers to turn trusted insights into business impact at scale and speed. We've helped hundreds of consumer-focused brands across the globe to transform into insights-driven businesses. Market leaders such as Unilever, Vodafone, Bayer, and Tesco are driving innovation and making smarter market moves with the support of Market Logic. Find out more at https://marketlogicsoftware.com/.About MatterMatter is an intelligence company for brand builders and experience creators. We help organisations gain the clarity and confidence they need to make decisions that unleash commercial success. Blending strategic rigour with creative craft, we transform complex data into simple, powerful intelligence that drives brand and experience performance. Clients-from ambitious startups to global enterprises-choose Matter for our ability to deliver fast, impactful, and beautifully executed work.Find out more at https://www.matter.nz/SOURCE: Market Logic Software, GmbH Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
CBL International Limited榮獲EcoVadis銀獎 躋身全球可持續發展表現前15%企業行列 ACN Newswire

CBL International Limited榮獲EcoVadis銀獎 躋身全球可持續發展表現前15%企業行列

吉隆坡, 2025年12月16日 - (亞太商訊 via SeaPRwire.com) - CBL International Limited(納斯達克股票代碼:BANL)(「公司」或「CBL」),萬利集團(「萬利」或「集團」)的上市主體,欣然宣布公司榮獲享有盛譽的EcoVadis銀獎,躋身全球可持續發展表現評估前15%的企業行列。EcoVadis銀獎認可CBL在四個關鍵維度上建立的穩健可持續發展管理體系和全面的企業責任方法:環境、勞工與人權、道德規範以及可持續採購。這一成就體現了公司將可持續發展融入核心業務運營和價值鏈的堅定承諾。萬利集團集團主席兼行政總裁謝威廉博士表示:「榮獲EcoVadis銀獎是一個重要的里程碑,驗證了我們對負責任商業實踐的持續投入。在CBL,可持續發展不是附加項,而是我們日常運營的核心。這一認可反映了我們團隊共同努力打造一個既能實現商業成功又能產生積極社會影響的企業。」EcoVadis評估基於聯合國全球契約、ISO 26000和國際勞工組織公約等國際標準,分析企業可持續發展管理體系,將CBL置於全球85%以上的領先位置。要獲得銀獎資格,CBL需在所有可持續發展主題上展現強勁表現,並在每個類別中達到嚴格的最低得分要求。這一成就正值CBL持續推進其可持續發展倡議之際,包括通過生物燃料分銷和新一代燃料開發致力於海事脫碳。公司最近報告2025年上半年生物燃料銷售額同比增長154.7%,展示了環境管理與業務增長如何相輔相成。CBL的可持續發展之旅包括可衡量的碳减排目標、道德供應鏈治理、社區投資項目以及透明的ESG報告。公司近期英國皇家特許管理會計師公會 2025年度大獎中榮獲「卓越可持續發展獎」,以及謝威廉博士獲得由香港董事學會(HKIoD)頒發的「年度董事大獎—上市企業執行董事類別」,進一步彰顯了其在可持續海事物流領域的領導地位。公司將繼續致力於提升可持續發展績效,計劃進一步加強環境倡議、增強社會影響項目,並深化與全球最佳實踐一致的治理框架。照片說明:CBL INTERNATIONAL LTD 榮獲EcoVadis銀獎,該獎項授予在獎牌頒發日期前 12 個月內由 EcoVadis 評估其可持續發展表現的全球前 15% 的公司。關於萬利集團 萬利集團成立於 2015 年,以CBL International Limited(納斯達克:BANL)在納斯達克股票市場上市。我們致力於為客戶提供一站式燃油供應服務,被業內稱為燃油供應服務商。我們主要通過當地實體供貨商為船舶提供燃油加注服務,遍布比利時、中國、香港、印度、日本、韓國、馬來西亞、毛里裘斯、巴拿馬、菲律賓、新加坡、台灣、泰國、土耳其和越南,共覆蓋65個港口。集團積極推動可持續燃料,並已取得ISCC EU和ISCC Plus認證。 如欲瞭解更多信息,請到集團網站 https://www.banle-intl.com 瀏覽。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
CBL International Limited Achieves EcoVadis Silver Medal, Ranking Among Top 15% Globally for Sustainability Performance ACN Newswire

CBL International Limited Achieves EcoVadis Silver Medal, Ranking Among Top 15% Globally for Sustainability Performance

KUALA LUMPUR, December 16, 2025 - (ACN Newswire via SeaPRwire.com) – CBL International Limited (NASDAQ: BANL) (the "Company" or "CBL"), the listing vehicle of the Banle Group ("Banle" or "the Group") is proud to announce it has been awarded the prestigious EcoVadis Silver Medal, placing the company among the top 15% of organizations globally assessed for sustainability performance.The EcoVadis Silver Medal recognizes CBL's robust sustainability management system and comprehensive approach to corporate responsibility across four key dimensions: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. This achievement reflects the company's commitment to integrating sustainability into its core business operations and value chain."Earning the EcoVadis Silver Medal is a significant milestone that validates our ongoing dedication to responsible business practices," said Dr. Teck Lim Chia, Chairman and CEO of Banle Group. "At CBL, sustainability isn't an add-on—it's embedded in how we operate daily. This recognition reflects our team's collective efforts to build a business that delivers both commercial success and positive societal impact."The EcoVadis assessment, which analyzes companies' sustainability management systems based on international standards including the UN Global Compact, ISO 26000, and ILO conventions, places CBL in the 85th percentile or higher globally. To qualify for the Silver Medal, CBL demonstrated strong performance across all sustainability themes, meeting rigorous minimum score requirements in each category.This achievement comes as CBL continues to advance its sustainability initiatives, including its commitment to maritime decarbonization through biofuel distribution and next-generation fuel development. The company has recently reported a 154.7% year-on-year surge in biofuel sales in the first half of 2025, demonstrating how environmental stewardship and business growth can go hand in hand.CBL's sustainability journey includes measurable carbon reduction targets, ethical supply chain governance, community investment programs, and transparent ESG reporting. The company's recent recognition with the "Excellent Sustainability Award" at the CGMA Annual Awards 2025 and "Directors of the Year Awards – Listed Companies Executive Directors category - Dr. Teck Lim Chia" presented by the Hong Kong Institute of Directors (HKIoD) further underscores its leadership position in sustainable maritime logistics.The company remains committed to advancing its sustainability performance, with plans to further strengthen its environmental initiatives, enhance social impact programs, and deepen governance frameworks in alignment with global best practices. Caption: CBL INTERNATIONAL LTD has been awarded the EcoVadis Silver Medal, a recognition granted to the top 15% of organizations globally assessed for sustainability performance by EcoVadis within the 12 months preceding the medal award date.About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications.For more information about our Company, please visit our website at: https://www.banle-intl.com. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares ACN Newswire

Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares

HONG KONG, December 15, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX: 1952.HK) today unveiled its 2030 strategy. Following the announcement, the Company’s shares strengthened during the trading session and briefly reached an intraday high of HKD 48.54. By market close, the stock was trading at HKD 46.88, with the share price remaining at relatively elevated levels throughout the session, representing a gain of 4.55%, indicating a positive market response.According to market commentary, the strong performance on the day reflected both investor focus on the Company’s newly articulated medium- to long-term strategy and confidence signals released earlier by Directors and substantial shareholder. Previously, the Company also announced that certain Directors and a substantial shareholder have increased their shareholdings in the Company. On December 12, 2025, Mr. Wei Fu, Non-executive Director, Honorary Chairman of the Board and a substantial shareholder of the Company; Mr. Yifang Wu, Executive Director and Chairman of the Board; Mr. Rogers Yongqing Luo, Executive Director and Chief Executive Officer; and Mr. Ian Ying Woo, Executive Director, President and Chief Financial Officer, collectively acquired 846,659 ordinary shares of the Company through open-market transactions, for a total consideration exceeding HK$38 million, representing an average price of approximately HK$45.01 per Share. In addition, the Company has been informed that CBC Group, a substantial shareholder of the Company, has further undertaken that it plans to increase its shareholding by not more than 1% in aggregate in the following three to six months, subject to the market conditions and compliance with applicable laws and regulatory requirements. The relevant actions are seen as a clear indication of Directors and substantial shareholders' positive stance on the company's long-term development prospects.The Company's 2030 strategy sets out a dual-engine approach to deliver predictable near-term growth and value creation through commercialization of existing assets, business development partnerships, and in-house R&D milestones, while driving long-term growth and value creation through in-house R&D and discovery, as well as global commercial expansion. Everest Medicines will continue to strengthen its leadership in core therapeutic areas, advance the development and commercialization of innovative therapies, and build a globally competitive biopharmaceutical company with sustainable growth.Everest Medicines focuses on renal, autoimmune, critical care, cardiovascular, and ophthalmic disease area, advancing its pipeline through a combination of in-licensed innovative assets and in-house R&D. By 2030, the Company aims to build a high-value commercial product portfolio while selectively expanding into additional valuable therapeutic areas with blockbuster potential.The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle. By 2030, Everest Medicines targets annual revenue exceeding RMB 15 billion, including approximately RMB 9 billion from its existing pipeline and RMB 6 billion from newly in-licensed assets, while also exploring potential out-licensing opportunities. Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafter. Over the same period, the number of commercial products is expected to exceed 20, including NEFECON®, Velsipity®, XERAVA®, cefepime–taniborbactam, and Lerodalcibep.To support its international growth, Everest Medicines is advancing a global strategy focused on strengthening regulatory and clinical development capabilities, while progressively building commercial infrastructure across Europe, the United States, and emerging markets. By 2030, the Company aims to drive growth through a combination of overseas out-licensing and direct commercialization, accelerating its global expansion.Notably, as a major shareholder of NovaBridge Biosciences, holding approximately 16% of its issued share capital, the Company will collaborate with NovaBridge Biosciences to identify high-quality assets and enhance global R&D and commercialization capabilities through complementary strengths and resources."The 2030 Strategy reflects Everest Medicines' clear vision for commercialization, R&D, and global expansion, and reinforces the Company's ability to deliver sustainable value. Since its founding in 2017, the Company has built a strong foundation through in-licensing innovative assets, completing its IPO, and executing a dual-engine strategy focused on high-potential therapeutic areas and strong commercialization and R&D capabilities," said Mr. Wei Fu, Honorary Chairman of the Board of Everest Medicines and CEO of CBC Group. "CBC Group will continue to leverage its global resources and ecosystem to support the Company's growth, spanning pipeline advancement, platform building, and organizational expansion. The recent share purchases by the Directors and CBC Group's announced intention to increase its shareholding further demonstrate strong confidence in Everest Medicines' long-term prospects.""The 2030 Strategy marks a key milestone for Everest Medicines, guiding growth through BD partnerships and in-house R&D to build a larger commercial portfolio and pursue new high-potential blockbuster opportunities. Leveraging its BD capabilities and the CBC ecosystem, the Company plans to add three-to-five late-stage, high-value assets annually, aiming for peak sales within three years of reimbursement, with more than 20 new assets expected to contribute around RMB 6 billion by 2030 and RMB 30 billion by 2035. Our strong balance sheet and cash flow from commercial activities will support the implementation of our strategic initiatives." said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "We will also continue to advance our in-house R&D platforms and, through our collaboration with Hasten, strengthen the late-stage pipeline and market reach.""Everest has established a scalable commercialization platform integrating medical, access, marketing, and sales capabilities," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "As a chronic disease therapy, NEFECON® generated over RMB 1 billion in sales during the first three quarters of its first full year following commercial launch, validating our commercial effectiveness. Building on this success, we will extend our commercial model and expertise from renal and anti-infective therapies to additional therapeutic areas, while advancing our in vivo mRNA CAR-T and mRNA tumor vaccine platforms, addressing unmet medical needs in China and globally."Overall, the release of Everest Medicines' 2030 strategy not only sets out a systematic roadmap for future business development but also, through proactive share purchases by Directors and substantial shareholder, reflects aligned internal and external confidence in the Company's long-term prospects. Looking ahead, guided by its dual-engine strategy, Everest Medicines aims to strengthen its position in core therapeutic areas and innovative drug R&D, while building a globally competitive biopharmaceutical company with sustainable growth. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
青島國資+雙管線驅動!華芢生物(02396.HK)破局PDGF稀缺賽道 錨定國配核心機遇 ACN Newswire

青島國資+雙管線驅動!華芢生物(02396.HK)破局PDGF稀缺賽道 錨定國配核心機遇

香港, 2025年12月16日 - (亞太商訊 via SeaPRwire.com) - 在全球創新藥估值修復與18A賽道稀缺標的爭奪白熱化的背景下,青島國資深度背書的華芢生物-B(02396.HK)正式啟動港股招股,以"港股PDGF第一股"的獨特定位,成為年末國際配售市場的核心聚焦點。公司擬全球發售1764.88萬股股份,其中國際配售占比90%(1588.38萬股),香港公開發售占比10%(176.50萬股),招股期至12月17日,最高發售價51.00港元,預計12月22日於港股主板掛牌。在同期六支新股並行、資金面分散的市場環境下,華芢生物憑藉糖足管線的全球稀缺性、難以複製的技術壁壘、清晰的商業化路徑及充足的現金流儲備,精准契合全球長線機構對"確定性成長+高壁壘資產"的配置邏輯,而其核心糖足管線Pro-101-2一旦實現商業化,將成為全球範圍內屈指可數的PDGF稀缺資產,開啟千億級創面癒合市場的價值重估。糖足特效藥的"全球存在"與"中國缺席":不是無藥,是"用不上"糖尿病足作為糖尿病最致命的慢性併發症,正以龐大的患者基數與嚴峻的治療現狀,催生千億級剛性醫療需求。根據世界衛生組織定義,糖尿病足是由神經病變和血管缺血引發的足部潰瘍、感染甚至組織壞死,嚴重時需截肢保命,其治療複雜且昂貴。據招股書披露,我國糖尿病患者已達1.4億,其中糖足患病人數已突破840萬,隨著老齡化加速與糖尿病年輕化趨勢加劇,這一數字仍在持續攀升。更令人揪心的是,糖足的致死致殘率居高不下,尤其是截肢患者年死亡率更是達到22%,遠超部分癌症,而傳統療法的局限性讓這一困境雪上加霜。當前臨床治療仍停留在"清創+抗生素+基礎護理"的傳統模式,無法解決血管神經病變導致的慢性創面修復障礙,癒合率長期低於50%,給醫保基金帶來沉重負擔。更嚴峻的是,全球範圍內PDGF藥物領域已沉寂27年——自1997年首款PDGF藥物Regranex獲FDA批准後,全球再無第二款同類產品上市,其15g規格售價高達1700美元,且未進入中國市場,國內患者難以企及。而國內市場長期處於國產PDGF藥物"零獲批"狀態,臨床需求與供給空白形成鮮明對比。而華芢生物核心糖足管線Pro-101-2作為已進入II期臨床階段的PDGF藥物,其"血管新生-組織修復"雙效機制可從根源上解決慢性創面癒合難題,每年為醫保基金節約超億元支出,完美契合醫保提質控費的核心訴求,具備強大的市場滲透潛力。弗若斯特沙利文數據顯示,2033年國內僅糖足市場規模將達485億元,而整個傷口癒合市場將突破1180億元,這片千億藍海正等待真正的破局者出現。技術護城河:13年積澱鑄就全球稀缺競爭力PDGF藥物並非普通企業可輕易涉足的領域,其背後是長達數十年的研發積澱、工藝突破與人才積累,從量變到質變的壁壘讓競爭對手望塵莫及,而華芢生物歷經13年深耕,已構建起"技術+工藝+專利"的三重護城河,成為全球PDGF領域的稀缺玩家。PDGF作為血小板損傷後分泌的強效生長因數,通過啟動細胞信號通路促進成纖維細胞增殖與肉芽生長,是慢性創面癒合的"黃金鑰匙",但其分子結構複雜、穩定性差、生產工藝嚴苛,成為全球藥企的研發禁區。華芢生物通過基因序列優化,剔除了5個易裂解氨基酸,顯著提升了藥物在人體內的穩定性與活性;生產端,公司採用畢赤酵母表達系統,相較於釀酒酵母,活性提升75倍,不僅解決了產能受限問題,更實現單位生產成本的大幅下探,打破了海外競品的天價壟斷,讓國內患者"用得上、用得起"保肢藥物。臨床數據充分驗證了技術突破的價值。Pro-101-2的I期臨床結果顯示其安全耐受性優良,無嚴重不良事件及死亡病例報告,而其針對中重度糖足的治療優勢尤為突出——可覆蓋Wagner1-3級患者,既能促進慢性創面癒合,更能阻止輕症向重症惡化,填補了國內中重度糖足治療的空白。該管線有望於2030年實現上市,成為國內首款糖足治療PDGF藥物。專利佈局方面,公司已構建54項已授權及待批專利矩陣,從分子序列、表達系統到製劑工藝、適應症拓展形成全鏈條保護,為競爭對手設置了難以突破的知識產權屏障。這種"技術+工藝+專利"的三重壁壘,讓PDGF賽道形成近乎獨家的競爭格局,而華芢生物作為唯一持續推進的企業,其稀缺性在全球創新藥領域尤為珍貴。商業化確定性:資金-研發-商業化正向閉環,鑄就機構青睞的 18A 稀缺標的對國際配售機構而言,清晰的商業化路徑與充足的資金儲備是規避研發型企業風險的核心,而華芢生物憑藉"糖足+燒燙傷"雙管線協同以及多重風險對沖優勢,成為"風險可量化、成長可預期"的稀缺配置標的。多重風險對沖優勢進一步強化了機構配置信心。青島國資作為核心股東,不僅為公司提供資金支持,更使其成為地方政府重點扶持的生物醫藥名片,在研發資源對接、政策協同、產業化等方面具備顯著優勢。其聯席保薦人中信證券2025年在18A賽道表現亮眼,保薦的7個專案均實現首日未破發,其中映恩生物、勁方醫藥等首日漲幅超100%,12月10日掛牌的寶濟藥業更是錄得3526.34倍公開發售認購、暗盤一度暴漲超115%的佳績,亦強化市場信心。更值得關注的是,公司已完成2000L規模商業化生產工藝,具備從臨床到商業化的完整技術銜接能力,且PDGF藥物通過縮短住院時間、降低截肢率,與DRG/DIP支付改革方向高度契合,商業化路徑明確。此外,公司具備"小流通盤+純正18A屬性"優勢,未來有望快速進入港股通,參考歷史數據,港股通納入後南向資金的持續配置將為股價提供顯著流動性溢價,契合機構對資產流動性的核心要求。在全球創新藥估值修復、18A賽道稀缺標的爭奪加劇的背景下,華芢生物正站在"國產PDGF第一股"的關鍵節點。其核心糖足管線Pro-101-2一旦實現商業化,將成為全球範圍內屈指可數的PDGF稀缺資產,打破27年的技術壟斷與市場空白,切入千億級剛需市場;而燒燙傷管線的率先落地將奠定現金流基礎,打開長期成長空間。對國際配售機構而言,這家兼具"國資護航+技術壁壘+剛需屬性+優質保薦+現金流閉環"的18A稀缺標的,不僅具備清晰的臨床推進路徑與商業化前景,更有望憑藉港股通預期與賽道稀缺性實現價值重估。華芢生物正迎來臨床價值與資本市場價值的雙重兌現期,為全球長線機構提供了年末佈局"確定性成長+高壁壘資產"的優選機遇,而其作為全球PDGF領域稀缺玩家的價值,也將在商業化進程中持續凸顯。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
康哲藥業(867.HK/8A8.SG):創新藥口服JAK1抑制劑Povorcitinib在中國獲納入「突破性治療品種」 ACN Newswire

康哲藥業(867.HK/8A8.SG):創新藥口服JAK1抑制劑Povorcitinib在中國獲納入「突破性治療品種」

深圳, 2025年12月16日 - (亞太商訊 via SeaPRwire.com) - 12月15日,康哲藥業控股有限公司(「康哲藥業」)欣然宣佈,旗下德鎂醫藥有限公司(「德鎂醫藥」,專業聚焦皮膚健康的創新型醫藥企業,正申請於香港聯合交易所有限公司主板獨立上市,詳見康哲藥業日期為2025年4月22日發佈的公告)擁有相關許可權利的創新口服JAK1抑制劑povorcitinib(擬定中文通用名:磷酸泊沃昔替尼片)(「povorcitinib」或「產品」)已獲中國國家藥品監督管理局(「NMPA」)藥品評審中心批准納入突破性治療品種名單,擬定適應症為成人患者非節段型白癜風。此次認定有望加快該產品的研發與審評進程。Povorcitinib是一種選擇性口服小分子JAK1抑制劑,在區域內特定國家/地區擁有物質和用途專利。Povorcitinib目前正在海外若干國家進行非節段型白癜風、中重度化膿性汗腺炎(HS)和結節性癢疹的3期臨床試驗。另外,治療哮喘的2期臨床試驗也在進行中。2023年3月,Incyte公佈povorcitinib達到了非節段型白癜風的全球多中心2b期臨床研究的主要終點。結果顯示:治療24周,與安慰劑相比,接受每日一次povorcitinib治療的患者的全身皮損顯著複色。隨後該2b期試驗的擴展期結果表明,長期使用povorcitinib可進一步促進全身和面部的複色,且耐受性良好[1]。2025年8月,德鎂醫藥獲NMPA簽發的藥物臨床試驗批准通知書,同意開展povorcitinib用於治療非節段型白癜風等適應症的臨床試驗。德鎂醫藥已啓動產品在中國的臨床開發工作,並考慮擇機在中國推動其治療HS和結節性癢疹等皮膚相關疾病的臨床開發。白癜風是一種慢性自身免疫性疾病,其特徵是皮膚色素脫失,其發病原因為產生色素的細胞即黑素細胞的缺失。據估算,中國約有1030萬人患有白癜風,其中約820萬人患有非節段型白癜風[2]。目前白癜風療法選擇有限且難以治療,特別是對於累及面積大的白癜風患者。若於中國獲批,povorcitinib有望為非節段型白癜風患者提供差異化的治療選擇。本次該產品獲納入突破性治療藥物品種名單,有望加速其在中國大陸的研發與審評進程。若於中國獲批上市,該產品將有望與德鎂醫藥在售創新藥益路取(替瑞奇珠單抗注射液)、在售獨家藥喜遼妥(多磺酸粘多糖乳膏)及正處於新藥上市申請(NDA)階段的創新藥磷酸蘆可替尼乳膏形成協同,推動產品快速實現臨床和商業價值,惠及更多皮膚疾病患者。此外,該產品還將與外用磷酸蘆可替尼乳膏共同為白癜風患者提供差異化、全面的治療選擇。康哲藥業於2024年3月31日,通過德鎂醫藥的附屬公司與Incyte就povorcitinib訂立合作和許可協議(「許可協議」),獲得在中國大陸、香港特別行政區、澳門特別行政區、臺灣地區及東南亞十一國(「區域」)研究、開發、註冊及商業化產品的獨家許可權利,以及在區域內生產產品的非獨家許可權利。德鎂醫藥的附屬公司已將povorcitinib除中國大陸外的其他區域的相關權利再許可予康哲藥業(不包括德鎂醫藥及其附屬公司)。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化,把控產品全生命週期管理的開放式平臺型企業,致力於提供有競爭力的產品和服務,滿足尚未滿足的醫療需求。康哲藥業專注於全球首創(FIC)及同類最優(BIC)的創新產品,並高效推進創新產品臨床研究開發和商業化進程,賦能科研成果向診療實踐的持續轉化,造福患者。康哲藥業聚焦專科領域,擁有被驗證的商業化能力,廣泛的管道覆蓋和多疾病領域專家資源,核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展,以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力,帶來專科規模效率,其中皮膚健康業務(德鎂醫藥)已成為其細分領域的龍頭企業,並擬於聯交所獨立上市。同時,康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展,以獲取新興市場的增量,助力集團實現高質量可持續發展。參考文獻/資料1. 產品非節段型白癜風適應症的全球多中心2b期臨床結果可在Incyte官網查詢:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-data-phase-2b-study-evaluating-povorcitinib2. 數據來自灼識諮詢報告康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣,非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊,請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請,不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制,但康哲藥業並無進行任何說明或保證、明述或暗示,或其他表述,對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述,該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證,存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測,康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
GMG Unveils Graphene Aluminium-Ion Battery That Fully Charges in 6 Minutes ACN Newswire

GMG Unveils Graphene Aluminium-Ion Battery That Fully Charges in 6 Minutes

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - December 15, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide the latest progress update on the Graphene Aluminium-Ion Battery technology ("G+AI") being developed by GMG and the University of Queensland ("UQ") under a Joint Development Agreement with Rio Tinto, one of the world's largest metals and mining groups, and with the support of the Battery Innovation Center of Indiana ("BIC") in the United States of America.Based on its current state of development as reflected below, the GMG G+AI Battery has similar performance characteristics to those provided by High Power Lithium Titanate Oxide ("LTO") batteries, which are sold at a premium price of up to US$1500/kWh. However, the GMG G+AI Battery can be produced at a substantially lower cost and therefore can be priced below that of LTO batteries. In 2025, sales of LTO batteries, which are used in many applications globally, totalled US$ 5.6[1] billion.Battery Performance Update:GMG is pleased to announce that it has progressed its G+AI Battery technology and believes that, once development is completed, it can meet the key target specification requirements for the main targeted battery use case as per Figure 1, including:Charging in under 6 minutes;Energy density > 100 Wh/kg after 1 hour of charging;Long Cycle Life (10,000 cycles);Safe (no Lithium);Lower Thermal Runaway Risk; andLikely no thermal management system will be needed.Bob Galyen, GMG Non-Executive Director, commented: "In my nearly five decades in the battery industry, I have rarely seen a technology with the disruptive potential of GMG's next-generation graphene aluminium-ion battery. With the possibility of charging from empty to full in around six minutes, this chemistry fundamentally changes how designers can think about electric vehicles, consumer electronics, and stationary storage. Instead of planning around long charge stops with large packs, engineers can optimise for rapid energy turnaround, with higher power, and safer, with GMG's battery made from abundant raw materials. Lithium-ion will remain a key part of the energy landscape for years to come, but its limitations in fast charging, temperature tolerance, and critical-mineral supply are increasingly evident. By leveraging aluminium and graphene, the GMG team is demonstrating a pathway to reduce reliance on traditional lithium-based systems while delivering step-change improvements in charge time and power density. This is not an incremental tweak to existing cells - it is a new platform that can open markets and use cases that were previously uneconomic or impractical. As GMG moves from the lab toward scaled manufacturing, its primary focus is on proving reliability, safety, and cost at industrial level. Automotive, grid, and specialty-device partners are already engaging with GMG to explore pilot programs and early integrations. The companies that adapt quickest to this shift will lead the next wave of electrification, and GMG intends to be at the centre of that transition with graphene aluminium-ion technology."Figure 1: G+AI Battery Use Case - heavy mobile equipmentTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_gmg_figure1.jpgGMG is pleased to share the energy densities of the current GMG G+AI pouch cell at 60 minutes and 6-minute charging compared to other chemistry batteries on the market (Figure 2), and a voltage vs capacity graph (Figure 3) of its latest G+AI Battery technology based on data provided by the third-party BIC battery testing laboratory.Based on that testing, the current stage of development, batteries produced by GMG and BIC had an energy density of 58 Wh/kg when charged in 1 hour and 26 Wh/kg when charged in 6 minutes. In 6-minute fast charging, the battery cells achieved 62% capacity in 3.2 minutes. The batteries had a nominal voltage of approximately 3.0 Volts and maintained performance over hundreds of cycles at 6-minute fast charging, without the significant degradation typically observed in lithium and sodium-ion batteries at such high charging rates.Figure 2: Different Battery Chemistry Performance at 6 min and 60 min Charge[2]To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_002full.jpgStandard commercial Lithium Nickel Manganese Cobalt ("LNMC") and Lithium Iron Phosphate ("LFP") battery cells for electric vehicles and stationary storage are not designed for continuous 6-minute charging (10C); typical recommended charge rates are ≤1 hour (1C), often 2 hours (0.5C), with only limited fast charge operation. Only specialized high-power cell designs like LTO battery cells can tolerate charge rates of 6 minutes (10C).[3]Figure 3: Battery performance curves of GMG's G+AI Battery at 60 min and 6min chargeTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_003full.jpgGMG has now developed a completely new hybrid electrolyte that is chloride free and noncorrosive, unlike common aluminium battery electrolytes, along with a complex cathode and anode technology that enables very stable fast charging over several cycles. The substrate for both the cathode and anode in the GMG G+AI Battery is aluminium foil - which provides significant cost and weight savings compared with copper, the substrate material used in most lithium and sodium-ion batteries. GMG's technology does not include the use of lithium or copper. The Company has submitted an additional patent application covering these new developments.Craig Nicol, GMG Managing Director and CEO, commented: "I couldn't be happier with the GMG team to get to this point with our battery. We have rebuilt this battery in our weekly sprints from the ground up and developed completely new complex cathode, anode and electrolyte. This will provide a next generation fast charging battery technology currently not available in the world, and we look forward to sending out sample cells to test with partners in early 2026. This technology has many years of development in front of it and will improve as we keep pushing through known issues to improve capacity, voltage and reduce weight."GMG management believes that the Company's battery technology can eventually achieve over 150 Wh/kg when charged in 1 hour, and over 75 Wh/kg when charged in 6 minutes. The Company believes further development of the cathode, anode, electrolyte and component weights will eventually achieve this end goal.Figure 4 shows the latest Graphene Aluminium-Ion Battery multi-layer pouch cell.Figure 4: Current Multi-Layer Battery Pouch CellTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_004full.jpgBattery Technology Readiness LevelThe battery technology readiness level ("BTRL") of the G+AI technology remains at Level 4, see Figure 5. GMG is currently optimizing electrochemical behaviour for pouch cells via ongoing laboratory experimentation. Through collaboration with BIC, it is anticipated that the battery technology readiness will progress to BTRL 7 and 8 since the equipment and processes needed to produce the G+AI batteries are the same as those employed to make Lithium-Ion Batteries.Figure 5: Battery Technology Readiness Level (BTRL)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_005full.jpgThe Company is confident it can meet the overall timeline, as seen in Figure 6, of its battery cell roadmap that calls for testing of cells with customers in 2026 and small commercial production with support of various partners, including BIC, in 2027.Figure 6: Battery Cell RoadmapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_006full.jpgNext Steps Toward Commercialisation & Market ApplicationsJack Perkowski, GMG Chairman and Non-Executive Director, commented: "I am extremely proud that GMG has progressed its battery to this stage. It is a significant milestone for the Company because the battery technology has so much opportunity in so many applications - especially in commercial vehicles. I look forward to the next updates as GMG makes further progress in the development of its battery technology."The Company continues to see a broad range of applications for a completed GMG G+AI Battery - utilising its ultra-high power-density and economic energy density characteristics. Along with Rio Tinto, a range of global companies have confidentially expressed their interest in working with GMG in the following vertical sectors:Figure 7: Market ApplicationsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_007full.jpgCurrently, GMG believes it will use a plastic battery pack design, similar to Figure 8, to hold the battery pouch cells - reducing the weight, cost and complexity of using a metal case. Using a plastic battery pack is possible for two main reasons - GMG believes that its battery will not require a thermal management system or the fireproofing precautions provided by the metal case in a lithium-ion battery. Using plastic will increase the comparative energy density of GMG's G+AI battery packs when compared to lithium-ion batteries.Figure 8: Expected Battery Pack for G+AIB Pouch CellsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_008full.jpgComparison and Market Review: LTO Batteries As shown in Figure 9 below, the performance of GMG's G+AI battery technology is already very similar to LTO batteries.Figure 9: Comparison of Graphene Aluminium-Ion Battery (G+AI) to Lithium Titanate Oxide (LTO) BatteryParameterHigh Power LTO[4]GMG G+AI BatteryRapid Charging80% in 6 minutes100% in 6 minutesEnergy Density - 6-minute charge37 Wh/kg (80% of Capacity)46 Wh/kg (6 min +)26 Wh/kg(Current)Large upside to be confirmedDepth of DischargeFull RangeFull RangeSafetySafeSafer (no lithium fire potential)Longevity70% performance over 20,000 cyclesTo be confirmedBattery PriceUS$800 - US$1500 / kWh[5]Lower price due to lower material costsNo lithium, no TitaniumMarket SizeUS$5.6 Billion in Sales in 2025Under development LTO batteries are sold at a premium to LFP and LNMC batteries, which are the main chemistries used in electric vehicles and energy storage systems, and are also widely used in other electronic applications due to their high performance and long cycle life. The material and manufacturing costs for GMG's G+AI Battery are expected to be similar to, or less than, the cost to manufacture standard lithium-ion batteries, but substantially lower than the costs to produce LTO batteries.LTO batteries have energy density ranging from 50 - 80 Wh/kg.[6] The LTO product is sold globally for use in many applications - with a total of US$5.6[7] billion sales per annum in 2025. Sales of LTO batteries are expected to grow at 10% per annum to an estimated US$ 9.0 billion by 2030. The major manufacturers of LTO batteries include Toshiba, Gree, Microvast and CATL.Further details on applications for the LTO battery from Mordor Intelligence7 are described below. In many of the use cases for LTO batteries, GMG believes that its G+AI Battery can be substituted at a substantially lower cost.Commercial Vehicles: Automotive, primarily buses, refuse trucks, and drayage tractors rather than passenger cars, is the largest user of LTO batteries. Fleets realize five-year total-cost-of-ownership parity once fuel savings and lower maintenance offset higher upfront prices.Fast-charging Electric Buses and Trucks: Transit authorities need battery systems that accept repeated high-power "opportunity charges" during short layovers. LTO cells replenish 80% capacity in roughly five minutes, allowing operators to shrink fleet size without sacrificing route frequency. U.S. Low-No Emission Bus grants earmark more than US$1.5 billion per year, with bid specifications that explicitly reference rapid-charge capability. Parallel subsidy programs in China reimburse up to CNY 80,000 (US$ 11,396) per new-energy bus, accelerating volume deployment in provincial capitals.Hybrid and BEV: Regenerative braking and high-C-rate acceleration favour the use of LTO batteries. Use in fast-charge EV stations is growing rapidly as ride-hailing fleets adopt swap-ready models.Stationary Storage: Utility-scale batteries now cycle multiple times per day for frequency regulation, peak shaving, and voltage support. Energy-storage-system integrators adopt LTO batteries for grid-frequency response where state-of-charge swings are shallow but frequent.Industrial Robotics: LTO batteries are used in continuous-duty forklifts that require partial charges during operator breaks.Aerospace and Defense: Unmanned aerial vehicles, missile auxiliaries, and soldier-worn power banks operating from -40 °C to +60 °C ambient.5-minute Battery-Swap Stations: Battery-as-a-service platforms require ultra-fast turnaround and high cycle life. CATL confirmed plans to install 1,000 swap stations in 2025 and 30,000-40,000 by 2030, each requiring packs that tolerate thousands of rapid exchanges without degradation.Sub-10 kWh Packs: Cordless construction tools, autonomous ground vehicles, and medical carts select LTO batteries to bypass daily pack swaps.12V starter replacement to Lead acid: GMG's G+AI battery technology would be a viable 12 V starter-battery replacement for lead-acid, offering lower weight, longer cycle life, good low-temperature performance and improved cold-cranking capability, together with excellent tolerance to storage at 0% state of charge. In suitable system designs, the chemistry's stable voltage behaviour can also reduce balancing requirements and simplify battery management, helping to lower overall system cost.Lifecycle Procurement Preference: Many government procurement frameworks now weigh lifecycle reliability higher than purchase price. For example, New Mexico awarded a US$ 400 million bus electrification contract that included stringent thermal-runaway resistance metrics. Europe's Clean Industrial Deal allocates capital for storage technologies that stabilize renewables, aligning well with LTO batteries' fast-response profile.Cylindrical Cells: accounted for 37.7% of LTO battery sales in 2024 as entrenched production lines and robust steel casings satisfied heavy-duty demand. Pouch designs address aerospace weight requirements and constrained dashboards in autonomous robots.Summary of Important Milestones for GMG's G+AI Battery Development: MonthImportant Milestones in the Development of the Graphene Aluminium Ion BatteryMay 2020GMG and UQ win Australian Research Council grant for Graphene battery developmenthttps://graphenemg.com/gmg-and-uq-wins-australian-research-council-grant-for-graphene-aluminium-ion-battery-development/ Apr 2021The University of Queensland and GMG kick off coin cell battery development projecthttps://graphenemg.com/gmg-the-university-of-queensland-research-uni-quest-kick-off-the-graphene-enhanced-aluminium-ion-battery-development-project/May 2021Graphene aluminium-ion battery performance data - Energy Density and Power Densityhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-performance-data/Jun 2021Graphene aluminium-ion battery performance data - Cycle Lifehttps://graphenemg.com/graphene-aluminium-ion-battery-performance-data/Jun 2021Significant potential battery customer market response to launch of batteryhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-progress-update/Jul 2021Investment decision for coin cell battery development centrehttps://graphenemg.com/gmg-battery-pilot-plant-investment/Oct 2021Construction starts for coin cell battery development centrehttps://graphenemg.com/construction-battery-pilotplant/Oct 2021Bosch Australia Manufacturing Solutions and GMG sign Letter of Intenthttps://graphenemg.com/gmg-and-bosch-sign-collaboration-arrangement-for-bosch-to-design-and-deliver-gmgs-graphene-aluminium-ion-battery-manufacturing-plant/Dec 2021Commencement coin cell battery development centrehttps://graphenemg.com/battery-pilot-plant/Dec 2021Initial coin cell batteries sent for customer feedbackhttps://graphenemg.com/graphene-aluminium-battery-customers-prototypes/Mar 2022Initial factory acceptance testing of semi-automated prototype battery cell assembly equipmenthttps://graphenemg.com/gmg-announces-initial-factory-acceptance-testing-of-semi-automated-prototype-battery-cell-assembly-equipment/Mar 2022Wood Engineering and GMG Sign a Letter of Intenthttps://graphenemg.com/gmg-and-wood-agree-collaboration-arrangement-for-wood-to-engineer-and-deliver-major-graphene-manufacturing-expansion-projects/May 2022Rio Tinto and GMG sign Letter of Intenthttps://graphenemg.com/gmg-riotinto-energysavings-battery/Jun 2022Commissioning of Pouch Cell Equipmenthttps://graphenemg.com/gmg-manufactures-first-pouch-cell/Jun 2022Bob Galyen, former chief technology officer of CATL, joins GMG technical advisory committee.https://graphenemg.com/gmg-technical-advisory-committee-leadership-team-additions-and-cfo-change/Aug 2022Investment decision for Phase 1 modular Graphene Production Planthttps://graphenemg.com/gmg-announces-phase-1-expansion-project-to-graphene-manufacturing-facility-for-energy-saving-products-and-batteries/Oct 2022Significant battery performance, cell and graphene production improvementshttps://graphenemg.com/gmgs-battery-update-significant-battery-performance-cell-and-graphene-production-improvements/Dec 2022Investment of $600k Battery Development Centrehttps://graphenemg.com/gmg-invests-au-600000-to-accelerate-battery-pouch-cell-customer-testing-development-in-2023/Feb 2023Australian Government Approval (AICIS) for production and sale of batteries.https://graphenemg.com/gmg-receives-regulatory-approval-to-enable-significant-commercial-sales/May 2023Battery Joint Development Agreement with Rio Tinto signedhttps://graphenemg.com/gmg-announces-battery-joint-development-agreement-with-rio-tinto/May 2023Battery Technology Readiness Level (BRTL) 2-3 reachedhttps://graphenemg.com/gmg-announces-battery-team-and-related-updates/May 2023Decision to switch to develop Pouch Cells (instead of Coin Cells)https://graphenemg.com/gmg-announces-battery-team-and-related-updates/Jul 2023Bob Galyen former chief technology officer of CATL joins GMG board of Directorshttps://graphenemg.com/graphene-manufacturing-group-appoints-former-chief-technology-officer-of-catl-limited-to-its-board-of-directors/Sep 2023Battery Pouch Cell Prototypes Multilayered Auto-Stacker Demonstrationhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-pouch-cell-prototypes-multilayered-auto-stacker-demonstration/Sep 2023Reaching 500 mAh capacity batteryhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Sep 2023Battery Technology Readiness Level (BRTL) 4 reachedhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Nov 2023Rio Tinto and GMG Partnership Video Launchedhttps://graphenemg.com/rio-tinto-gmg-battery-partnership-video-launch/Dec 2023Commissioning of modular Graphene Production Planthttps://graphenemg.com/graphene-manufacturing-group-commissions-modular-graphene-production-plant/Feb 20241000 mAh Capacity Reachedhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-1000-mah-capacity-reached-and-next-steps-toward-commercialisation/Mar 2024Graphene Manufacturing Group Secures AU$2 million Funding Grant from Queensland Government for Battery Pilot Planthttps://graphenemg.com/graphene-manufacturing-group-secures-au2-million-funding-grant-from-queensland-government-for-battery-pilot-plant/Aug 2024GMG's Graphene Aluminium-Ion Battery: Progress Update and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-progress-update-and-next-steps-toward-commercialisation/Mar 2025GMG's Graphene Aluminium-Ion Battery: Collaboration with World Leading USA Battery Innovation Centre and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-collaboration-with-world-leading-usa-battery-innovation-centre-and-next-steps-toward-commercialisation/ About BIC:BIC is a collaborative initiative designed to incorporate leadership from renowned universities, government agencies, and commercial enterprises. BIC is a public-private partnership and a not-for-profit organization focusing on the rapid development, testing and commercialization of safe, reliable and lightweight energy storage systems for defense and commercial customers. BIC is a unique organization that has been leading battery cell development for world leading battery companies for over 10 years and has carried out over 500 battery development projects.About GMGGMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041www.graphenemg.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the lower cost to produce GMG G+AI batteries, expectations for GMG G+AI batteries in respect of charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system when development is completed, that the new hybrid electrolyte is chloride free and non-corrosive, that the cathode and anode technology employed enables very fast and stable charging, that GMG G+AI batteries provide significant cost and weight savings relative to copper, that G+AI batteries can achieve over 150 Wh/kg charged over 1 hour and 75 Wh/kg when charged over 6 minutes following further development of cathode, anode, electrolyte and component weights, that G+AI batteries will progress to BTRL 7 and 8, that the timeline for the battery cell roadmap is achievable, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and which offers weight, cost and complexity advantages to a metal case and increased energy density, expectations for the lack of a thermal management system or fireproofing precautions, expectations for material and manufacturing costs, expectations for sales of LTO batteries, expectations for G+AI batteries being substitutable for LTO batteries at lower cost, expectations that G+AI batteries are viable 12V starter battery replacements and the rationale therefor and the advantages of pouch design for aerospace weight requirements and constrained dashboards of autonomous robots.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions that GMG G+AI batteries can be produced at lower cost, as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries, the speed and stability of charging, that G+AI batteries will progress to BTRL 7 and 8, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and offer weight, cost and complexity advantages to a metal case and increased energy density, that the service agreement with the BIC will enable the Company to optimize its cell design and battery manufacturing equipment, and that the Company will be able to meet its overall timeline on the battery cell roadmap. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that GMG G+AI batteries cannot be produced at lower cost, or any of the assumptions as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries can not be achieved, G+AI batteries do not offer expected speed and stability of charging, that G+AI batteries will not progress to BTRL 7 and 8, that a range of global companies in a variety of industries will not be interested in working with GMG, that the battery pack design will not be plastic and not offer weight, cost and complexity advantages to a metal case and increased energy density, that the Company will not be able to optimize the electrochemical behaviour of the pouch cell through laboratory experimentation or at all, that the Company will not be able to meet its overall timeline on the battery cell roadmap, that the service agreement with the BIC will not enable the Company to optimize its cell design and battery manufacturing equipment and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 04, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.[1] Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends Report[2] LFP: https://www.evlithium.com/catl-battery-cell/catl-150ah-lifepo4-battery-cell.htmlLNMC: https://keheng-battery.com/product/catl-nmc-3-7v-151ah-high-energy-density-battery-for-ev/LTO: https://www.global.toshiba/ww/products-solutions/battery/scib/product-next/product/cell/high-power.htmlLead Acid: https://www.altronics.com.au/p/s4530-12v-3.5ah-sealed-lead-acid-sla-battery/?srsltid=AfmBOoqZGMEIsX__YYOuRLC3nvYDFtNkf35qZYuYeoh3ACf4wrrOLISD[3] https://findingspress.org/article/21459-impact-of-charging-rates-on-electric-vehicle-batt[4] High-power type cells | SCiB™ Rechargeable battery | Toshiba[5] https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.[6] https://www.grepow.com/blog/battery-energy-density.html[7] Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends ReportTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/278044 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China ACN Newswire

CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China

SHENZHEN, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing.In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile[1]. In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future.Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo.The Product's inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options.The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries).About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-data-phase-2b-study-evaluating-povorcitinib2. Datas are from the China Insights Consultancy (CIC) reportCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

希迪智駕招股進行中:構築智能駕駛產業化底座 多場景落地打開成長空間

香港, 2025年12月15日 - (亞太商訊 via SeaPRwire.com) - 在全球新一輪科技革命與產業變革加速演進的背景下,智能駕駛產業正迎來爆發式增長,作為深耕該領域的核心力量,希迪智駕(3881.HK)于12月11日正式啟動招股程序,目前相關工作正有序推進中,公司赴港上市進程已進入最後衝刺階段,距離登陸港股資本市場僅一步之遙。全面技術體系:從算法到系統工程的縱深掌控自動駕駛作為集感知、決策、控制、調度、通信於一體的複雜系統工程,對企業的技術掌控力與全鏈條集成能力提出極高要求。自創立以來,希迪智駕便堅持技術自主化,通過組建專業研發團隊,體系化地開發了高效算法、軟件、子系統及場景模塊,覆蓋自動駕駛各個方面,從而開發出行業領先的產品及解決方案。在感知與算法層面,希迪智駕融合多元傳感技術與深度學習算法,實現全天候高魯棒性的目標識別與環境理解,適應礦區揚塵、震動干擾、交通交互等多樣化環境。在決策和控制層面,希迪智駕開發了基於場景驅動的路徑規劃機制與多車協同調度系統,支持多車動態調度、穩定運行。在系統工程層面,公司搭建了遠程接管平台、車載計算系統、V2X通訊模塊與調度中台,形成端到端的全閉環部署能力。希迪智駕目前在中國擁有513項專利申請和362項註冊專利,其中包括170項發明專利、107項實用新型專利和85項外觀設計專利,覆蓋算法、調度邏輯等關鍵核心領域,充分體現了其核心技術的深度與廣度。依託全面自主技術體系,希迪智駕在確保安全的前提下,不僅能快速迭代產品、降本增效,也使其在快速發展的產業環境中,擁有對技術命脈的掌控權與更強的成本控制能力,從而完成項目交付與升級閉環,在行業內建立起深厚的技術護城河。場景落地夯實商業根基 為後續增長提供強勁動力以技術為基石,希迪智駕深耕B端核心場景,在商用車、礦區、港口、園區等領域構建起顯著競爭優勢,憑藉成熟的量產能力與標杆客戶背書,實現商業化落地與規模化營收的雙重突破。在國內市場,希迪智駕打造了多個具有行業里程碑意義的標杆項目,贏得戰略合作夥伴的廣泛信任。在自主採礦領域,公司於江蘇省句容市為TCC交付了中國首個完全無人駕駛純電採礦車隊,該項目同時也是全國首個通過NIM認證的自主採礦項目,作業效率遠超傳統人工採礦;在西北區域,其打造的有人與無人駕駛採礦混編車隊,規模位居中國(含香港、澳門及臺灣)第一;在河南鄭州,自主研發的全無人駕駛採石場系統實現與挖機的協同作業,成為行業技術應用新標杆。在V2X領域,自2018年自主研發的V2X設備實現初步商業化以來,希迪智駕持續突破,創新推出V2X+主動式公交信號優先系統,並在重慶市兩江新區建設最大的國家級車聯 網先導區之一的過程中發揮了關鍵作用。在智能感知領域,公司成為業內首批為列車交付前裝量產自主感知系統的企業之一,相關成果獲業界廣泛認可。商業化成果的持續落地轉化為堅實的經營數據。截至2025年6月30日,希迪智駕已向客戶交付414輛(套)自動駕駛礦卡(系统),同時收到647輛(套)自動駕駛礦卡(系统)的指示性訂單,訂單儲備充足,為後續增長提供強勁動力。依託國內項目的成功經驗,希迪智駕積極推進全球化佈局,將成熟的業務模式複製至海外市場,在多個海外地區建立穩固的客戶關係與市場根基,成功簽署多個海外項目,全球化發展戰略成效顯著。從自動駕駛底層技術突破到場景級產品集成,希迪智駕構建出一條極具技術深度與商業廣度的成長路徑。通過「自研+集成+協同」的技術體系,公司不僅跑通了多場景落地,也建立起面向未來的持續演進機制。在港上市後,公司將充分借助國際資本市場的多元資源優勢,繼續深化技術創新,積極拓展全球應用場景邊界,在智能駕駛產業的高速發展中,持續以技術突破賦能產業升級,以創新活力引領行業前行,其長期增長潛力值得高度期待。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
雲頂新耀發佈2030戰略規劃 管理層及主要股東增持超3800萬港元股份 ACN Newswire

雲頂新耀發佈2030戰略規劃 管理層及主要股東增持超3800萬港元股份

香港, 2025年12月15日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀(HKEX 1952.HK)發佈公司2030發展戰略。受戰略發佈提振,公司股價當日整體表現強勁,盤中一度觸及48.54港元的階段高點。截至當日收市,雲頂新耀股價報46.88港元,上漲4.55%,股價全天維持在相對高位運行,顯示市場反應積極。市場認為,當日股價的強勢表現,既反映了投資者對公司中長期戰略方向的認可,也與此前管理層及主要股東釋放的信心信號密切相關。此前於12月12日,雲頂新耀對外披露董事及主要股東增持公司股份的相關公告,多位管理層成員通過公開市場合計增持公司普通股846,659股,涉及總金額超過3,800萬港元;同時,主要股東康橋資本亦承諾將在未來三至六個月內,在視市場情況及符合法律監管要求的前提下,進一步增持公司股份。相關舉措被視為管理層及核心股東對公司長期發展前景的明確表態。雲頂新耀2030戰略明確提出以「BD合作+自研」雙輪驅動,實現商業化創造確定性價值、自研創造成長性價值。公司將持續鞏固核心治療領域優勢,推進創新藥研發和商業化,打造可持續增長的全球化創新型生物制藥企業。公司聚焦腎科、自身免疫、急重症、心血管及眼科等核心方向,通過引進創新資產與自主研發並行推進,到2030年形成高價值產品組合,並拓展其他藍海領域的大單品。商業化平台建設方面,公司已布局三款商業化產品,並著力建立全渠道商業化體系及藥品全生命周期商業化能力。到2030年,公司計劃實現收入規模超過150億元人民幣,其中現有管線銷售收入約90億元,新引進管線銷售收入約60億元,並探索潛在對外授權(License-out)收入;年複合增長率預計在2025-2030年超過50%,2030年後保持超過15%。同時,商業化產品數量將提升至20款以上,包括耐賦康®、維適平®、依嘉®、頭孢吡肟-他尼硼巴坦及樂瑞泊®(萊達西貝普)等。研發平台方面,公司以擁有全球權益的自研mRNA平台為基礎,持續推進現有管線,同時通過引進及生態孵化潛力平台拓展研發能力。到2030年,在核心平台mRNA in vivo CAR-T和mRNA腫瘤疫苗平台基礎上,擴展至其他高潛力平台(比如siRNA、抗體等),進一步強化核心治療領域研發實力。全球化能力建設方面,公司啟動全球化戰略,推進全球化的注冊及臨床開發能力建設,同時逐步自建歐美及新興市場商業化體系,盡快實現「海外授權+商業化」的雙引擎驅動增長,加快國際化發展步伐。值得一提的是,作為新橋生物的第一大股東(持股約16%)及重要戰略投資者,雲頂新耀還計劃與新橋生物深度協同,發掘優質資產,加強全球化研發能力建設,並通過創新藥商業化整合平台及「BD合作+自研」雙輪驅動模式,進一步拓展全球商業化及研發注冊能力。同時借助新橋生物在不限治療領域的全球化產業資源、團隊及頂尖人才,實現雙方優勢互補。雲頂新耀董事會榮譽主席、康橋資本首席執行官傅唯先生表示:「雲頂新耀發佈的2030戰略充分體現了公司在創新藥研發、商業化和全球化布局上的清晰規劃與前瞻性,展示了持續創造價值的能力。自2017年成立以來,公司通過授權引進(license-in)引入創新資產,建立了堅實的基礎,完成在香港交易所IPO,並依靠『雙輪』驅動戰略,聚焦藍海領域,打造卓越商業化平台並完善研發和生產能力,為公司未來發展奠定了堅實基礎。康橋資本將充分發揮全球產業資源和生態網絡優勢,與公司共享戰略與運營經驗,支持核心管線和研發平台的持續發展。作為主要股東,我們也通過增持股份進一步表達對公司長期發展前景的認可和支持。期待公司在未來持續引領創新藥研發與商業化發展,打造全球領先的綜合性生物制藥企業。」雲頂新耀董事會主席吳以芳先生強調:「2030戰略標志著雲頂新耀邁向全球生物制藥前沿的重要里程碑。未來五年,公司將聚焦『BD合作+自研』雙輪驅動,依托科學與市場洞察,推動戰略領域形成N+X產品組合,把握藍海大單品機遇。公司計劃通過已經建立的BD能力和康橋生態,每年引進3-5個中後期重磅產品,依托自身精幹高效的商業化團隊實現每個產品醫保後三年銷售達峰。未來五年,公司計劃引進20個以上的高值資產,為2030年貢獻收入60億,在2035年實現大約300億的收入貢獻。在自研方面,公司將持續推進創新藥自主研發平台建設,強化核心治療領域研發能力。同時,公司近期與海森生物簽署的商業化服務協議及授權許可協議,將充實後期管線布局、提升商業化平台運營效率,並助力心血管及相關領域業務拓展。未來,公司將持續推動管線拓展、商業化能力建設及全球研發佈局,不斷提升雲頂新耀在全球創新藥領域的綜合競爭力。在商業化現金流持續改善及充裕現金儲備的有力支撐下,公司將加快戰略落地,穩步邁向千億市值計劃的目標,為更多患者帶來高價值的創新治療選擇。」雲頂新耀首席執行官羅永慶先生表示:「通過深化『雙輪驅動』戰略,雲頂新耀正加速邁向全球領先的生物制藥公司。公司已建立以『科學及商業洞察驅動的醫學、准入、市場、銷售一體化協同』為核心的商業化體系,並持續強化平台能力建設,推動核心產品穩健增長。作為一款慢病用藥,耐賦康®在上市後的首個完整商業化年度,依靠不到200人的一線銷售團隊,今年前3季度銷售額已突破10億元成為行業最佳實踐之一,充分驗證了公司成熟且可複制的商業化能力。基於此,公司將把在腎科及抗感染領域積累的商業化體系與經驗,拓展至自身免疫、眼科、急重症及心血管等治療領域。科學及商業洞察也是研發的戰略出發點,我們將同時加速推進自研mRNA In vivo CAR-T平台及mRNA腫瘤疫苗平台的臨床開發進程。在2030戰略指引下,雲頂新耀將持續聚焦中國及全球尚未滿足的醫療需求,不斷提升全球創新藥競爭力,為更多患者帶來高價值創新治療選擇。」整體來看,雲頂新耀此次發佈的2030戰略,不僅系統規劃了未來發展的業務路徑,更通過管理層與主要股東的主動增持行動,體現了內外一致的戰略認同與長期信心。展望未來,在「雙輪驅動」戰略的持續引領下,雲頂新耀將繼續鞏固在核心治療領域和創新藥研發上的優勢,穩步邁向可持續增長的全球化生物制藥企業目標,成為全球領先的綜合性生物制藥公司。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Indonesia’s KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge ACN Newswire

Indonesia’s KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge

JAKARTA, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - Indonesia's state-owned railway operator PT Kereta Api Indonesia (KAI) has rolled out two major initiatives aimed at strengthening national mobility and accelerating its digital shift: the launch of the Farmer and Trader Train on the Merak Commuter Line, and the expansion of face recognition boarding technology ahead of the 2025/2026 Christmas and New Year travel season.Farmer-Trader train to facilitate the movement of agricultural goods, processed food, and small-scale merchandise by providing dedicated cargo space within a commuter railway environment.KAI said the programs reflect its commitment to inclusive transport services while enhancing operational efficiency and environmental performance — moves that align with international railway modernization trends.A special passenger train featuring oversized windows and often a large glass roof (sunroof) to provide unobstructed, wide-angle views of the passing scenery, turning the journey itself into a scenic experience."KAI is committed to building a rail ecosystem that supports grassroots economies while adopting technologies that meet global service standards," said KAI President Director Bobby Rasyidin. "These initiatives reinforce railways as an inclusive, efficient, and sustainable mode of public transport."New Farmer–Trader Train Strengthens Local Product DistributionEffective 1 December 2025, KAI began operating the Farmer and Trader Train on the Merak–Rangkasbitung corridor in Banten Province. The service is designed to facilitate the movement of agricultural goods, processed food, and small-scale merchandise by providing dedicated cargo space within a commuter railway environment.The rolling stock was fully redesigned by Balai Yasa Surabaya Gubeng, KAI's technical workshop, which modified the interior layout, baggage sections, loading–unloading access points, and safety signage to meet the needs of micro and small enterprises."The train has been engineered by our in-house experts to ensure safe, orderly, and convenient goods movement without disrupting passenger flow," continued Rasyidin.The service operates under a government-funded Public Service Obligation (PSO) scheme with a flat fare of Rp3,000, allowing up to two cargo units per user. It is attached to 14 daily Commuter Line services and stops at 11 stations across coastal and agricultural areas.On launch day, 95 customers used the service, carrying agricultural produce, snacks, and handicrafts for markets in Serang, Cilegon, and Merak. KAI expects the service to reduce traders' reliance on road-based logistics and shift more local supply chains onto rail.Rasyidin said the initiative strengthens regional economic resilience: "Reliable logistics access for small producers is fundamental to local economies. This service opens a more predictable distribution channel for farmers and traders."Facial Recognition Technology Boosts Efficiency, Cuts WasteKAI is also expanding its facial recognition boarding system to improve passenger processing and reduce paper usage in major stations.KAI VP Public Relations Anne Purba, explains, between January and October 2025, the feature recorded 9.29 million uses, cutting ticket paper consumption by 23,245 rolls, equivalent to Rp341 million in savings. Since the system debuted in 2023, it has been used by 19.4 million passengers, contributing significantly to KAI's environmental and cost-reduction goals."Facial recognition shortens boarding time and significantly reduces paper waste, supporting more environmentally responsible operations," Purba said.The technology is now available in 22 stations, with wider deployment planned ahead of peak holiday travel to reduce queues and streamline passenger flow.Purba underscored the strategic value of automation: "Digitalization is not just innovation—it is increasingly essential to managing national mobility at scale. This system helps maintain operational stability when travel demand peaks."Holiday Ticket Sales Climb, Discounts ExpandedDemand for the year-end holiday period—18 December 2025 to 4 January 2026—continues to rise. As of 26 November, KAI had sold 629,060 tickets, or 21.15% of the roughly 3 million seats available.To support affordability and smooth travel, KAI is offering 30% discounts for 156 regular services and 26 additional economy-class trains, totaling 1.5 million discounted seats valid from 22 December to 10 January.Purba said higher mobility is expected across Java and Sumatra: "We are preparing large capacity and fare incentives to ensure safe, orderly, and accessible travel throughout the holiday season."Inclusive and Technology-Driven Mobility for IndonesiaBy combining inclusive rural-focused services with large-scale digital transformation, KAI aims to bring Indonesia's rail sector closer to global standards of accessibility, efficiency, and sustainability."Our strategy aligns with international efforts to build modern public transport systems that deliver broad social and economic impact," Purba concluded.For More Information, please contact:Anne PurbaVP Public RelationsPT Kereta Api Indonesia (Persero)Source: PT Kereta Api Indonesia (Persero), https://www.kai.id Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations ACN Newswire

TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations

TransNusa Launched 11 International Routes in 3 YearsIndonesia-based PT TransNusa Mandiri Aviation grows a strong brand with expansion focusing on international routesTransNusa focuses on international tourism island destinations to offer domestic and foreign tourists increased air connectivityTransNusa introduces four new domestic scheduled direct flights to boost connectivity from Bali to Lombok and Bima as well as between renowned diving destinations Manado to Sorong and Sorong to Timika, world’s largest gold mining islandJAKARTA, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - TransNusa has successfully launched four new domestic routes today, securing 19 routes in total within three years of operations.TransNusa Group CEO, aviation veteran, Datuk Bernard Francis, known for his acute, unique and out-of-the-box turnaround and change management strategies, led TransNusa towards a secure yet bold growth pattern using a customized business model, which was specifically developed to suit the changing market demand after the onslaught of the pandemic.“What we envisioned for TransNusa was to build an Indonesian-based airline with strong fundamentals. Today, thanks to our hard working and diligent team, the TransNusa brand has grown to resonates confidence and trust,” said Datuk Bernard, adding that TransNusa’s shareholder, China Aircraft Leasing Group Holdings Limited (CALC) and business partners also played a large role in helping build TransNusa into the strong brand it is today.Within 6 months of its operations, TransNusa launched its first international route between Jakarta and Kuala Lumpur, followed by three additional international routes in that same year, including Singapore and China.TransNusa also implemented a milestones as well as initiated and developed new domestic routes, such as the Bali-Manado route.In addition, TransNusa the first Indonesian airline to operate regular scheduled international flights into Guanzhou from three destinations in Indonesia.Datuk Bernard said the primary factor in the successful growth of TransNusa, in the last three years, was their goal to implement a lasting and impactful change around not just the organisation and its people but also its business model and operations.“In TransNusa, a 100% change is not possible overnight, whereas a 5% change in a moderate manner is not only more feasible but allows for a lasting change,” said Datuk Bernard, explaining that it was that principal which has been the backbone of TransNusa's operations and growth.On the new domestic route launches, Datuk Bernard said that TransNusa hopes to provide increased connectivity and travelling options to domestic and international tourists.“We would like to play our part in boosting and increasing air connectivity within Indonesia’s internationally renowned tourism island destinations.“Our focus is in increasing direct flight to destinations that are world renowned for its unique and stunning landscape and natural offerings,” said Datuk Bernard.DATUK BERNARD FRANCIS… TransNusa's team and business partners contributed to the growth of the airline and it’s brand.Flight DetailsTransNusa’s flight from Bali to Lombok will operate two times daily beginning Monday, December 15. The TransNusa flight will depart Bali from the Denpasar International Airport at 07.30am and arrive in Lombok International Airport at 07.55am, with the return flight departing Lombok at 08.25am and arriving in Bali at 09.05am. The second TransNusa flight will depart Bali at 15.55pm and arrive in Lombok at 16.50pm, with the return flight departing Lombok at 17.20pm and arriving in Bali at 18.05pm.“We will increase the frequency of the scheduled flights for the Bali-Lombok route to three times daily on December 21.” Said Datuk Bernard.The third scheduled flight will depart Bali at 18.55pm and arrive at Lombok at 19.35pm. The scheduled flight from Lombok will depart at 20.00pm and arrive in Bali at 20.25pm.Meanwhile, TransNusa’s flight from Bali to Bima will also begin on Monday, December 15.“For the first week, we will operate one scheduled flight from Bali to Bima on Monday, Wednesday, Friday and Sunday.“Starting December 22, TransNusa will operate daily scheduled flights from Bali to Bima,” said Datuk Bernard, adding that the flight will depart Bali from the Denpasar International Airport at 09.35am and arrive at 10.35am at the Sultan Muhammad Salahuddin Airport in Bima.The return flight will depart Bima’s Sultan Muhammad Salahuddin Airport at 11.00am and arrive at Bali’s Denpasar International Airport at 12.10pm.Meanwhile, TransNusa’s schedule flight from Sorong to Timika will operate four times weekly on Monday, Tuesday, Thursday and Saturday.The flight, which will also begin on December 15, will depart Sorong from the Domine Eduard Osok International Airport at 10.50am and arrive in Timika’s Mozes Kilangin Airport at 12.10pm. The return flight will depart Timika at 12.40pm and arrive in Sorong at 14.00pm.On the much sought-after Manado-Sorong route, Datuk Bernard said that TransNusa’s will operate its scheduled flight from Manado to Sorong four times weekly.The scheduled flight from diving haven Manado will operate on Monday, Tuesday, Thursday and Saturday. The flight will depart Manado’s Sam Ratulangi International AIrport at 08.00am and arrive in Sorong’s Domine Eduard Osok International Airport at 10.20am. The return flight will depart Sorong at 14.30pm and arrive in Manado at 14.50pm.TransNusa, A Short HistoryThe 3-year old TransNusa, led by aviation expert and veteran, Datuk Bernard, made waves in the aviation industry with its unique domestic and international business development and growth strategy.Within just 6 months of operations, in 2023, the airline, known then as a new player with new rules, launched its first international route between Jakarta and Kuala Lumpur, followed by the launch of scheduled flights between Jakarta and Singapore.TransNusa, which established itself as a Premium Service Carrier, made headlines in Malaysia, Singapore, China and around the world with news of being the first airline in Indonesia to introduce new exciting routes. In 2023, during its first year of operations, TransNusa became the second Indonesian airline to receive approval to fly to China. In 2024, TransNusa became the first in the world to develop and introduce a new domestic route connecting Bali and Manado. In October 2025, TransNusa added yet another milestones by becoming the first Indonesian airline and second airline in the world to launch scheduled flights from Manado to Guangzhou, China.Media Contact:Trina Thomas RajMobile: +6012 4992672E-mail: trina@myqaseh.org Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
國資護航+技術壁壘+優質保薦 華芢生物(02396.HK)PDGF管線直指18A賽道確定性價值 ACN Newswire

國資護航+技術壁壘+優質保薦 華芢生物(02396.HK)PDGF管線直指18A賽道確定性價值

香港, 2025年12月15日 - (亞太商訊 via SeaPRwire.com) - 12月12日,華芢生物-B(02396.HK)正式開啟招股,公司擬全球發售1764.88萬股股份,其中香港發售股份176.50萬股,國際發售股份1588.38萬股,附帶264.72萬股超額配股權,招股期至12月17日,最高發售價51.00港元,中國生物制藥領域也將迎來重磅IPO。據悉,華芢生物深耕傷口癒合領域,在糖尿病足(糖足)領域取得突破性進展,精准卡位老齡化及糖尿病年輕化萬億級剛需市場。依託青島高科(嶗山區財政局全資控股的國資平台)的產業資源整合能力與政策協同優勢,疊加自主搭建的"蛋白+核酸"雙技術平台及覆蓋14個適應症的差異化管線佈局,以及行業頂尖高管團隊加持,為港股市場投資者構築起抵禦18A生物科技企業高風險的安全邊際。市場普遍將其視為繼寶濟藥業之後又一具備高成長潛力的港股18A標的——不僅擁有扎實的臨床進展和清晰的商業化路徑,更兼具稀缺性與確定性,有望成為下一個被資本市場深度挖掘的價值明星。銀髮浪潮疊加年輕化趨勢:糖足治療剛需市場再擴容據國家統計局數據,全國60周歲及以上人口達3.1億(占總人口22.0%),其中65歲以上人群占比突破15.6%。老齡化加速催生糖尿病防控壓力,而與此同時,糖尿病年輕化趨勢正進一步擴大患者基數,形成"銀髮群體為主、青年群體補充"的雙重市場增量。弗若斯特沙利文報告顯示,我國糖尿病患者約1.4億,四分之一的糖尿病患者會在某個階段發展為糖足,2024年中國的糖足患病人數為840萬人。而當前GLP-1類減肥藥(如司美格魯肽)因減重效果顯著成為"網紅神藥",但其作用機制聚焦於抑制食欲與延緩胃排空,對糖足等血管神經病變類併發症無實質改善。與此同時,術後傷口癒合市場規模同樣超千億,傳統治療手段痛點顯著。在糖足治療領域,已從傳統外科清創轉向生物製劑主導的精准修復時代。中國糖足患者基數龐大,傳統療法(清創+抗生素)因無法解決血管神經病變導致的慢性創面修復障礙,臨床癒合率長期低於50%。PDGF(血小板衍生生長因數)類藥物憑藉其獨特的"血管新生-組織修復"雙效機制,能夠特異性啟動特定受體,促進成纖維細胞增殖與毛細血管生成,顯著加速創面癒合進程,成為千億級慢病管理與術後修復賽道的重磅增長引擎。華芢生物正是瞄準這一藍海市場,向"港股PDGF第一股"發起衝擊。技術突破+醫保減負:核心產品創造多重價值即便處於高研發投入期,華芢生物仍通過自主研發實現關鍵突破——優化核心技術序列並革新生產工藝,構建起差異化競爭優勢。其核心產品Pro-101-1的IIa期數據顯示,可使淺/深二度燒傷癒合時間縮短約7天,較傳統療法效率提升25%,這一突破為患者、醫療體系與醫保基金創造多重價值。對糖足及燒傷患者而言,癒合時間縮短能直接減少住院時長與家庭護理成本,降低因術後恢復導致的誤工、護理人員誤工等間接經濟損失,堪稱"糖尿病足患者的福音";對醫療體系來說,患者住院週期縮短可提高病床周轉率,減少醫療資源佔用,緩解醫護人員工作壓力;對醫保基金而言,治療週期縮短與再治療需求降低,能有效減輕醫保支出負擔,契合當前醫療保障體系降本增效的核心訴求。從技術平台來看,華芢生物以自主搭建的蛋白質藥物技術平台為核心,形成"蛋白+核酸"雙輪創新架構:酵母表達系統通過工藝革新提升蛋白生產效率,雙引擎協同支撐燒傷修復、糖尿病足潰瘍、脫髮治療等核心產品的臨床轉化,同時展現出向腫瘤疫苗、罕見病領域延展的技術潛力,為長期發展奠定技術基礎。國資托底+高管賦能+頂尖平台+強力護航:四重保障化解研發與市場風險生物制藥的研發向來充滿不確定性,一款新藥從實驗室到上市往往九死一生。但在華芢生物這裏,這種風險似乎被巧妙地拆解成了可控變數。在股權與資源端,青島高科產業發展有限公司(嶗山區財政局全資控股的國資平台)作為核心股東,通過持股17.32%(全球發售後相關類別股份)形成長期綁定,其國資屬性為公司在地方醫療資源對接、政策協調中奠定信任基礎,成為連接區域產業生態與研發管線的關鍵紐帶。在管理端,公司獲MNC大廠高管賦能,迎來兩位行業頂尖人才加盟,進一步強化創新發展底氣。其中,苗天祥先生曾是"外資藥企中國掌門人"代表,擁有近30年輝瑞中國工作經歷,曾任輝瑞中國大中華區主席,在財務、企業管理及制藥行業積累深厚經驗,現任華芢生物執行董事兼首席戰略官,負責制定、實施和監督公司整體戰略規劃,為企業把握行業方向、推進研發與市場佈局提供關鍵指導;宋冰女士曾長期任職於頂尖國際投行高盛高華證券,擔任總經理兼首席運營官,在金融投資、企業戰略及資本運作領域具備極強創造力與領導力,現任公司監事會主席,為整體規劃提供建議與監督,助力優化資源整合、提升資本運作效率。兩位核心高管的"組合賦能",與研發團隊技術創新形成合力,讓華芢生物在PDGF藥物研發與市場拓展中具備獨特優勢。在資本端,本次IPO由中信證券擔任聯席保薦人。值得一提的是,中信證券2025年在港股18A生物科技IPO領域表現亮眼,其保薦的其中7個專案均實現首日未破發,映恩生物、勁方醫藥等專案首日漲幅超100%,12月10日掛牌的寶濟藥業更錄得3526.34倍公開發售認購、暗盤一度暴漲超115%的佳績,中慧生物、旺山旺水也分別創下4007.64倍、6238.42倍的超高認購,充分獲得機構及專業投資者認可,為後續二級市場投資者提供堅實信心支撐。在管線端,公司"階梯式"研發管線進一步降低風險。目前,用於治療深二度燒燙傷的產品Pro-101-1,已完成IIb期臨床試驗的統計數據分析,用於治療淺二度燒燙傷的,已完成最後一例患者出組;用於治療糖尿病足潰瘍(糖足)的產品Pro-101-2正處於II期臨床試驗階段。未來,PDGF也有望應用於普通外科、牙科、皮膚科等近20個適應症。就連看似"跨界"的脫髮微針產品Pro-104,也已規劃在2029年提交IND申請。這種"成熟產品貢獻現金流、在研管線儲備未來"的佈局,像極了跨國藥企的經典打法——即便某一管線受挫,也不至於動搖根基。稀缺標的+港股通預期:投資者的優質選擇從市場屬性來看,華芢生物是"小而美"的稀缺標的,當前發行規模適中,流通盤較小,疊加清晰的盈利路徑與高壁壘技術平台,使其具備極強的流動性溢價潛力。市場普遍預期其在滿足市值與流動性條件後有望快速納入港股通,吸引南向資金配置,進一步放大賺錢效應。儘管近期港股市場有6支新股同步發售,資金面承壓,但華芢生物憑藉其純正的18A生物科技屬性,明確的臨床里程碑及國資背景與高管優勢,在年末IPO窗口中脫穎而出。對投資者而言,"國資背書+技術平台+管線梯隊+高管賦能"的組合,讓風險更可量化,契合長期資本對確定性增長的需求。在老齡化加速與創新藥政策紅利共振下,華芢生物以"癒合剛需+技術壁壘+國資護航+高管賦能"構建起獨特價值座標。對於尋求確定性增長的長期資本而言,這家即將登陸港交所的生物制藥新星,或將成為對沖行業波動、捕捉結構性機會的優質標的。其扎實技術與管線積澱更將為港股創新藥板塊注入新動能,推動PDGF藥物行業創新升級,專業投資市場亦在期待其更長期的價值兌現。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
京東工業登陸港交所:業績與品牌雙賦能 長期成長潛力可期 ACN Newswire

京東工業登陸港交所:業績與品牌雙賦能 長期成長潛力可期

香港, 2025年12月12日 - (亞太商訊 via SeaPRwire.com) - 12月11日,中國領先的工業供應鏈技術與服務提供商 - 京東工業(股份代號:7618.HK)正式登陸香港聯合交易所。作為工業供應鏈領域的標杆企業,京東工業的上市不僅是自身發展的里程碑,更為港股市場注入了一支兼具成長力與盈利能力的優質標的。數智化重構價值 財務表現彰顯成長實力作為行業領軍者,京東工業以數智化能力重構工業供應鏈價值。公司通過「太璞」這一「數」(數智)、「實」(商品)結合的全鏈路數智化工業供應鏈解決方案,提供廣泛的工業品供應和數智化供應鏈服務,精准匹配客戶的多元化需求,實現供應鏈效率與成本控制的雙重提升。財務數據是京東工業成長潛力的最直接印證。近年來,公司業績呈現“高增長、高盈利”的雙優態勢,持續經營業務總收入從2022年的人民幣(下同)141億元,穩步增長至2023年的173億元,2024年進一步攀升至204億元,複合年增長率高達20.1%;盈利能力更實現高速穩健增長,2022年,公司錄得经调整淨利潤7.1億元,而2024年大幅攀升至9.1億元,展現出強勁的盈利轉化能力。2025年上半年,公司業績持續釋放,期內公司實現持續經營業務總收入103億元,經調整淨利潤達5.0億元,較上年同期保持高速增長,在複雜的市場環境中展現出穩健的盈利能力與可持續的增長潛力。品牌生態相互協同 構築行業龍頭地位強大的品牌影響力和供應鏈能力為京東工業的發展奠定了堅實基礎。依託JD.com的深厚積澱,公司自成立以來便建立起良好的品牌認可度。值得一提的是,JD.com在2025年《財富》世界500強榜單中位列第44位,作為中國領先的在線零售商,其在商品質量與正品保障上的嚴苛標準,早已成為電商行業的標杆。借助這一優質品牌背書,京東工業成功滲透至多個垂直行業的高價值客戶群體,不僅構建了廣泛的品牌認知,更深化了客戶忠誠度。京東生態系統的協同效應更成為公司的核心競爭力之一。京東工業全面繼承並持續複用京東集團在供應鏈領域的核心優勢,包括一流的技術研發平台、深耕行業的產品知識儲備、覆蓋全國的完善物流服務網絡,以及專業的人才梯隊,這些資源的協同賦能,推動公司在技術創新與服務升級上不斷突破。多重優勢疊加持下,京東工業已確立穩固的行業龍頭地位。截至目前,公司已成為中國MRO採購服務市場的最大參與者,根據灼識諮詢的資料顯示,按2024年的交易額計,公司排名第一,規模為第二名的近三倍。同時,隨著業務向全工業供應鏈領域拓展,公司亦以4.1%的市場份額,成為中國工業供應鏈技術與服務市場的領軍企業。總體而言,京東工業憑藉數智化核心能力、穩健的財務表現及強大的品牌與生態協同優勢,在工業供應鏈這一高增長賽道上構建了深厚壁壘。此次登陸港交所,不僅為公司搭建起更為廣闊的資本運作平台,更標誌著其開啟了與全球投資者共享發展紅利的新征程。展望未來,隨著中國工業數字化轉型的加速推進,京東工業的增長空間有望持續拓寬,長期投資價值值得期待。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
京東工業配售結果出爐:MRO龍頭實力領跑 全鏈條數智化解決方案釋放長期價值 ACN Newswire

京東工業配售結果出爐:MRO龍頭實力領跑 全鏈條數智化解決方案釋放長期價值

香港, 2025年12月12日 - (亞太商訊 via SeaPRwire.com) - 12月10日,京东工业股份有限公司(「京東工業」或「公司」,股份代號:7618.HK)正式公佈全球發售配發結果。公司最終發售價格確定為每股14.10港元,香港公開發售部分反響熱烈,實現60.52倍超額認購,共接收超過7萬份有效申請,最終發售數目為21,121,000股,占全球發售股份總數的約10%;國際配售部分同樣表現亮眼,超額認購倍數約為7.88倍。雙重超額認購的市場反饋,充分彰顯了全球投資者對京東工業商業模式與發展潛力的高度認可。全鏈條解決方案鑄就領先地位 端到端數智化基礎設施賦能龐大客戶群作為中國領先的工業供應鏈技術與服務提供商,京東工業以「太璞」全鏈路數智化解決方案為核心競爭力,構建起「數」(數智)+「實」(商品)深度融合的服務體系,為企業客戶提供覆蓋廣泛的工業品供應及數智化供應鏈服務。通過這一體系,公司能夠有效滿足客戶在保供、降本、增效及合規等多維度需求,推動工業供應鏈領域的數字化變革。憑藉深厚的行業積澱,京東工業確立了市場領先地位,已成為中國MRO採購服務市場的最大參與者,根據灼識諮詢的資料顯示,按2024年的交易額計,公司不僅是中國MRO採購服務市場的龍頭企業,規模接近第二名的三倍,同時也是中國工業供應鏈技術與服務市場的最大服務提供商,市場份額達4.1%,行業標杆地位凸顯。這一地位的背後,是京東工業構建的端到端數智化基礎設施。基於服務千萬企業客戶的實戰經驗,公司打造的「太璞」解決方案,實現了「數」(數智)與「實」(商品)相結合,通過將數智化能力深度賦能客戶,引領企業採購供應鏈的數智化轉型。其核心價值在於踐行「讓數據多跑路,讓商品少跑路」的理念,使供需對接更順暢、匹配更精准、協同更高效,從根本上提升工業供應鏈的整體韌性與敏捷度。二十餘年京東集團供應鏈管理經驗的傳承,為京東工業積澱了深厚的專業知識儲備。在此基礎上,公司不斷迭代自身的供應鏈專業知識,在產品、客戶、垂直行業及供應商等領域實現突破,形成了強大的綜合競爭力。根據灼識諮詢的資料,截至2024年12月31日,公司的SKU數量冠絕中國工業供應鏈技術與服務市場;截至2025年6月30日,SKU數量已增至約8110萬個,2025年6月30日前十二個月內服務重點企業客戶約11100個。高客戶粘性進一步印證其服務價值,2024年重點企業客戶交易額存留率達105.7%,充分體現了客戶對其服務的高度信賴與持續認可。收入與盈利高速增長 數字化浪潮助力打開增長空間受益於行業數字化轉型浪潮及自身核心能力的持續釋放,京東工業近年來業績實現穩步增長。公司持續經營業務總收入從2022年的人民幣(下同)141億元,增長至2023年的173億元,2024年進一步攀升至204億元,複合年增長率達20.1%;從半年期數據看,截至2025年6月30日止六個月,公司持續經營業務總收入達103億元,較上年同期實現顯著增長。同時,公司盈利能力同步實現快速提升,2022年,公司錄得经调整淨利潤7.1億元,而2024年已大幅攀升至9.1億元,2025年上半年,公司延續高增長態勢,经调整淨利潤達5.0億元,較上年同期保持高速增長,展現出強勁的盈利韌性與增長持續性。關於募集資金的用途,京東工業在招股書中已作出明確披露:約35%的募集資金淨額計劃在未來48至60個月內用於於進一步增強公司的工業供應鏈能力;約25%的資金淨額將投入跨地域業務擴張;約30%的資金淨額預留用於潛在戰略投資或收購;剩餘約10%的資金淨額則將用於一般公司用途及補充營運資金,為整體業務的平穩運行築牢保障。一系列清晰詳實的資金規劃,既錨定了業務的持續升級與穩健擴張方向,亦彰顯出公司強勁的發展活力與健康向好的經營態勢。從行業角度來看,中國工業供應鏈市場的數字化滲透率目前仍處於較低水平,存在巨大的提升空間,根據灼識諮詢的資料顯示,中國工業供應鏈市場的數字化滲透率在2024年僅為6.2%,預計到2029年將達到8.2%。數字化滲透率的提高預計將推動工業供應鏈技術與服務市場規模快速增長,由2024年的人民幣0.7萬億元增至2029年的人民幣1.1萬億元,複合年增長率達到9.8%,廣闊的市場空間為京東工業提供了充足的增長動能。京東工業作為工業供應鏈數智化轉型的領航者,既擁有技術賦能的核心優勢,又具備市場領先的規模效應,更手握行業增長的時代機遇。憑藉獨特的業務模式、覆蓋全鏈路的服務能力及持續迭代的創新實力,在港上市後,公司將持續拓展服務邊界與深度,長期增長潛力巨大,有望在實現自身持續成長的同時,為投資者創造長期、穩定的價值回報。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More